RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

(A Govt. of Rajasthan Undertaking)

Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India Tel No: 0141-2228066, 2228064, E-mail: rmsc@nic.in, edprocurement@gmail.com

E-BID FOR THE ANNUAL RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES FOR THE YEAR 2014-15



LAST DATE OF SUBMISSION OF ONLINE BIDS:- 19.06.2014

Ministry of Health & Family Welfare Government of Rajasthan

RMSCL

"Mukhyamantri Nishulak DavaYojana" Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India Tel No: 0141-2228066, 2228064, E-mail: edprocurement@gmail.com

Ref. No.: F.02(126)/RMSC/PROCURMENT/DRUG/NIB-05/2014/485 Dated : 12.05.2014

Notice Inviting E-Bids

E-bids are invited upto 1.30 PM of 19.06.2014 for the Annual Rate Contract cum Supply and Empanelment of drug and medicines for the year 2014-15. Details may be seen in the Bidding Documents at our office or at the website of State Public procurement Portal http://sppp.raj.nic.in, www.dipronline.org, http://eproc.rajasthan.gov.in., www.rmsc.nic.in and may be downloaded from there.

Executive Director (Procurement) RMSCL

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

E-BID FOR THE ANNUAL RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES FOR THE YEAR 2014-15

Bid Reference : F.02(126)/RMSC/PROCURMENT/

:

DRUG/ NIB-03/2014/485 .

Dated 12.05.2014

Pre- bid conference : **29.05.2014** at **11.30** A.M.

(RMSC meeting Hall)

Date and time for downloading

bid document

: 22.05.2014 from 07.00 PM

Last date and time of submission

of online bids and e-deposit

19.06.2014 at 1.30 PM

Date and time of opening of

Online technical bids

19.06.2014 at 2.30 PM

Cost of the Bid Document : Rs. 2000/-

For SSI Unit of Rajasthan : Rs. 1000/-

RISL Processing Fees : **Rs. 1000/-**

Empanelment Fee : Rs. 5000/-

(If applying for Empanelment also)

<u>INDEX</u>

S.NO	PARTICULARS	
	General instruction for bidders	
1.	Last date for receipt of bids, bid document fees, Bid Security Deposit, RISL	
	processing fees and empanelment fees	
2.	Eligibility criteria	
3.	Purchase preference	
4.	General conditions	
5.	Technical bid	
6.	Price bid	
7.	Opening of technical and financial evaluation	
8.	Bid security deposit	
9.	Other conditions	
10.	Acceptance of bid	
11.	Security deposit(performance guarantee)	
12.	Agreement	
13.	Supply conditions Leading to the second sec	
14.	Logograms / markings	
15. 16.	Packing Overlity testing	
17.	Quality testing Payment provisions	
18.	Payment provisions Deduction in payments	
19.	Deduction in payments: Quality control deduction & other penalties:	
20.	Empanelment of firms	
21.	Saving clause	
22.	Jurisdiction	
23.	Correction of arithmetic errors:	
24.	Procuring entity's right to vary quantity:	
25.	Dividing quantities among more than one bidder at (in case of procurement of	
25.	goods):	
26.	Grievance redressal during procurement process:	
27.	Compliance with the code of integrity and no conflict of interest:	
28.	Fall Clause	
29.	Annexure-I Bank Challan	
30.	Annexure -II Format of Affidavit	
31.	Annexure -III Annual Turn Over Statement	
32.	Annexure -IV Agreement	
33.	Annexure - V Check List	
34.	Annexure - VI Check List of Details Regarding Products Quoted	
35.	Annexure - VII Declaration & Undertaking	
36.	Annexure - VIII List of Drugs With Specifications	
37.	Annexure - IX Guidelines for Blacklisting/Debarring of Product or Supplier/Company	
38.	Annexure - X Memorandum of Appeal Under The Rajasthan Transparency In Public Procurement Act, 2012	
39.	Annexure -XI Undertaking For Empanelment	
40.	Annexure -XII Supplier Consolidated Invoice	
41.	Annexure -XIII Analytical Report Regarding Quality	
42.	Annexure -XIV Security form (Bank guarantee)	

GENERAL INSTRUCTION FOR BIDDERS

The bidders are instructed to read the complete bid document carefully. The following points may be noted so that mistakes/lapses/shortcomings during Bid submission may be avoided.

- 1. It is expected from all bidders that they will ensure that documents to be used in bid set will be given to a reliable person only, and that only a fully reliable person shall be authorized for DSC. So that the confidentiality of your bid/rates is maintained upto bid opening & that your documents are not put to any misuse.
- 2. Complaints lodged in RMSC should bear signature, name, Id proof and mobile number of the complainant. This is important as RMSC has received many complaints in the past on letter heads of certain companies who later on denied to have made the complaint upon their verification. Rather, a few companies have asked RMSC to take action against those persons who have fraudulently made use of their letter heads. Therefore, unauthenticated complaints may not be acted upon.
- 3. In case you are given any assurance of any advantage in RMSC, by anybody or if you are directly or indirectly threatened or intimidated of harming your bidding & subsequent work in RMSC, please inform immediately about the same to MD, RMSC or ED(Proc.) RMSC. It would be better if evidence of such unfair activity of such person is produced so that action can be taken against such person / institution and their details can be put on the website.
- 4. It is advisable for you to authorize only those persons for RMSC tender who are employed in your company on salary basis.
- 5. If any firm, etc intends to lodge a complaint against a bidder with regard to bid (bid Condition), it may do so within 21 days of opening of technical bid, in the office of RMSC. After the stipulated period, it will not be possible to act upon the complaint.
- 6. The turnover should be as per bid conditions. Do not submit Bid if the turnover of the firm is less.
- 7. Do not quote the products manufactured on Loan license basis.
- 8. Quote only for the products for which your Product Permission meets the Bid specifications. Do not quote if it differs with regard to any parameter.
- 9. Quote rate in BOQ for the packing exactly given in annexure VIII. For example if the packing is given for 10x10 tablets, the rate should be quoted for 10x10 tablets, and not for 1 tablet or 10 tablets, similarly if the packing

- unit in the Bid specifies 2 ml ampoule (25 ampoules), the rate should be for 25 ampoules and not for 1 ampoule or 10 ampoules.
- 10. Highlight the quoted items in the documents like Product Permission and Market Standing Certificate, and also mark the item code no. at appropriate place in the documents.
- 11. The uploaded product permission and other documents should be clearly legible. Date of issue of the documents should be clearly legible.
- 12. Upload the Bids on the e-portal well in advance so that failure in uploading can be avoided and no desired document remains un-uploaded.
- 13. In case there is any suggestion regarding Bid conditions/specifications/shelf life, strength, packing/turn over etc. The suggestions should be submitted/sent/E Mailed one/two days earlier from the date of prebid meeting so that the representation of the bidders may be well processed and decision could be taken well in time.
- 14. If there is any query in Bid document/uploading process, you may contact Dr. Sanjay Pareek, Sr. Manager (Procurement Drugs) Mob.No.-09414489214 Sh. Nawal Kishore Sharma, Manager (Procurement) Mob.No. 09461300555

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

E-BID FOR THE ANNUAL RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES FOR THE YEAR 2014-15

Rajasthan Medical Services Corporation Ltd., (hereinafter referred as Bids Inviting Authority unless the context otherwise requires) E-BID FOR THE ANNUAL RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES FOR THE YEAR 2014-15

1. LAST DATE FOR RECEIPT OF BIDS, BID DOCUMENT FEES, BID SECURITY DEPOSIT, RISL PROCESSING FEES AND EMPANELMENT FEES

- (a) E-Bids [in two separate bids (Technical bid & Price Bid)] will be received till 19.06.2014 at 1.30 PM by the Rajasthan Medical Services Corporation Ltd, for the annual rate contract cum supply and empanelment for supply of drugs and medicines.
- (b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity for another period of 30 days. The Bidder may refuse extension of bid validity without forfeiting the Bid security deposit.
- (c) The e-Bids will be received on web-portal of e-procurement of GoR. Every Bidder will be required to pay the Bid form fee Rs. 2000.00 (Rs. 1000.00 for SSI Units of Rajasthan) for downloaded from the website, Bid Security Deposit as applicable in Bid condition no. 8 and processing fee of Rs.1000.00 of R.I.S.L. through three separate prescribed challans (*format enclosed in Annexure-I*) in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country upto 18.06.2014 or through D.D. / bankers cheque in favour of M.D. RMSCL (Bid document fees and Bid security), MD, RISL (Bid processing fees) physically in the office of RMSC by 1.30 PM on 19.06.2014. *Alternatively bidder may also*

deposit Bid document fees, Bid security and RISL processing fees by way of e-deposit, through Internet Banking by accessing RMSC website rmsc.nic.in clicking e-deposit icon following the laid down steps; Rs.25 plus applicable service tax will be the per transaction charge to be debited in respective depositor's account after successful e-deposit. Supplier should enclose the generated receipt. The bidders shall submit/upload scanned copy of all the challans/DD/ e - deposit generated receipt in Technical Bid. Bids will be opened only after ensuring receipt of Bid document fees along with processing fees and Bid Security Deposit. In the absence of Bid document fees and processing fees and Bid Security Deposit the Bids will be rejected and will not be opened.

Note:- (I) While the Bid uploading it would be asked on e procurement website about Bid Security, whether it is Rs. 2.00 lacs or Rs. 5.00 lacs, the bidder may mention any option for the purpose of Bid uploading but has to submit required Bid Security as specified in clause no 8.

Note:- (II) There is no option of online payment of tender fee, processing fee, bid security etc. on e-procurement portal. Therefore the bidder is advised to submit the required fees and bid security through internet banking only by accessing RMSC website www.rmsc.nic.in.

Click on offline mode (either DD or BC) on e procurement portal for the purpose of bid uploading only.

(d) Those who wish to apply for Empanelment as supplier for Drugs and Medicines are required to deposit separately an Empanelment Fee of Rs 5000 (Five Thousand rupees only) in the form of DD (in favour of MD, RMSCL)/challan/e-deposit before due time and date of bid submission. Please see clause 20 and Annexure-XI in this regard.

Note:-The bidders who have already paid empanelment fees in previous bid need not to submit the empanelment fee for the items being quoted in this bid. However the required annexure must be submitted.

2. ELIGIBILITY CRITERIA

- (a) Bidder shall be a manufacturer having valid own manufacturing license or direct importer holding valid import license. Distributors/ Suppliers / Agents/Loan licensee are not eligible to participate in the Bids.
- (b) Average Annual turnover (for drugs and medicines including Surgical and sutures Business) in the last three financial y
- (c) ears (2010-11, 2011-12 and 2012-13 or 2011-12, 2012-13 and 2013-14) shall not be less than Rs. 20 Crores. For SSI units of Rajasthan, the average annual turnover in the last three financial years (2010-11, 2011-12 and 2012-13 or 2011-12, 2012-13 and 2013-14 should not be less than Rs. 2 Crores. For drug items falling in the category of Disinfectants & Antiseptics, Eye preparations and Ear drops (Item code 221, 245, 319, 320, 330, 423, 425, 447, 484, 485, 486, 487, 564, 571, 572, 585, 587, 588, 589, 594, 611, 612, 613, 614) the average annual turnover of last three financial years should not be less than Rs. 2 Cr. And for item code 285 the average annual turnover of last three financial years should not be less than Rs. 10 Cr.
- (d) Bidder should have at least 3 years market standing as a manufacturer for the items quoted in the bid, on the date of bid opening. In the case of imported products, the product should have minimum 3 years standing in the market. The importer should have at least 3 years standing as manufacturer/importer of drugs in general. Imported drugs shall be accepted in brand name also.
- (e) Bidder should have permission to manufacture the item /drug quoted as per specification given in the Bid, from the competent authority. Product permission of *brands* shall be accepted in the Bid submitted, but the Bidder has to submit the product permission in generic names at the time of signing of the agreement/before supply.
- (f) Bid should not be submitted for the product/products for which the concern/company stands blacklisted/banned/debarred either by Bid inviting Authority or Govt. of Rajasthan or its departments on any ground.
 - The Bid should not be submitted for those products also for which the concern/company stands blacklisted/banned/debarred by any other State/Central

- Govt. or it's any agencies (central Drugs procurement agencies) on the ground of conviction by court of law or the products being found spurious or adulterated.
- (g) The concern/company/firm which stands blacklisted/banned/debarred on any ground either by Bid Inviting Authority (RMSC) or Govt. of Rajasthan or its departments on the date of bid submission, shall not be eligible to participate in the Bid.
 - The concern/company/firm which stands blacklisted/banned/debarred on the ground of conviction by court of law or the products being found spurious or adulterated by any other State /Central Government or it's any agencies (central Drugs procurement agencies) shall also not be eligible to participate in the Bid. For Specific cases regarding other quality issues the purchase committee of RMSC may decide the case on merit basis.
- (h) If any product/products of a company/firm have been declared as not of standard quality, as per Drugs & Cosmetics Act during last 2 years anywhere, such concern/company/firm shall not be eligible to participate in Bid for such product/products. If any company/firm is found to have any such product quoted in the Bid, the product shall be blacklisted for 2 years and a penalty equivalent to Bid Security Deposit shall also be levied. In such situation, the bid will be considered further only if the amount of penalty is deposited before the completion of technical evaluation.
- (i) The concern/firm/company whose product has been declared as of spurious or adulterated quality and any criminal case is filed and pending in any court shall not be eligible to participate for that particular product, in the Bid. Similarly convicted firm/company shall also not be eligible to participate in the Bid.
- (j) If a company has two or more separate manufacturing units at different sites/states, the company will be allowed to submit only one Bid for all units but necessary document regarding separate manufacturing units will be submitted as a separate set with the same Bid. But a bidder will be allowed to submit only one offer for one product.

3. PURCHASE PREFERENCE

i. Purchase preference admissible to the PSUs of the state of Rajasthan and to the SSI of the state of Rajasthan, together shall not exceed 25% (10% for PSUs and

15% of SSI units). However these units will be required to participate in Bidding process and match L-1 price.

ii. Comparison of rates of firms outside and those in Rajasthan:-

While tabulating the Bids of those firms which are not entitled to price preference, the element of Rajasthan VAT shall be excluded from the rates quoted by the firms of Rajasthan and the element of CST shall be included in the rates quoted by the firms of outside Rajasthan. In such case if the price of any commodity being offered for sale by firms in Rajasthan is the same or lower (excluding Rajasthan VAT) than the price of firm outside Rajasthan (including element of CST), the commodity shall be purchased from the firm in Rajasthan.

- iii. VAT on drugs and medicines are exempted in Rajasthan. RMSCL will issue necessary exempted certificate.
- iv. RMSC will also issue "C-certificate" in case of interstate supply. Therefore concessional CST should be charged

4. GENERAL CONDITIONS

- i. At any time prior to the date of submission of Bid, Bid Inviting Authority may, for any reason, whether on his own initiatives or in response to a clarification requested by a prospective Bidder, modify the condition in Bid documents by amendment. In order to provide reasonable time to take the amendment into account in preparing their bid, Bid Inviting Authority may at his discretion, extended the date and time for submission of Bids.
- ii. Interested eligible Bidders may obtain further information in this regard from the office of the Bid Inviting Authority.
- iii. In case any document submitted by the bidder or his authorized representative is found to be forged, false or fabricated, the bid will be rejected and Bid Security Deposit /Performance Security will be forfeited. Bidder/his representative may also be blacklisted/banned/debarred. Report with police station may also be filed against such bidder/his representative.

5. TECHNICAL BID

The Bidder should furnish the following in technical bid:-

(a) Bidders are allowed the option to quote for anyone item or more items as mentioned in bid (list of medicines proposed to be purchased at Annexure-VIII). The amount of Bid Security Deposit will remain @ Rs.

- 20,000/- per item of drug quoted subject to minimum of Rs.2.00 lacs and maximum of Rs.5.00 lacs.
- (b) The bidders shall submit/upload scanned copy of all the challans, D.D./ BC/ e-deposit generated receipt in Technical Bid deposited for Bid document fees, RISL processing fee and Bid security. The required Bid Security Deposit / Bid document fees/ RISL fee may be in form of physical D.D./ BC along with letter. D.D. / bankers cheque shall be in favour of M.D. RMSCL (bid document fees and Bid Security Deposit), MD, RISL (bid processing fees).
- (c) Those who wish to apply for Empanelment as supplier for Drugs and Medicines are required to deposit separately an Empanelment Fee of Rs 5000 (Five Thousand rupees only) in the form of DD /challan/e-deposit in favour of MD, RMSCL before due time and date of bid submission.
- (d) Documentary evidence for the constitution of the company/Firm such as Memorandum and Articles of Association, Partnership Deed etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director/Partners/Proprietor.
- (e) The Bidder should furnish attested copy of the valid License for the product duly approved by the Licensing authority for each and every product quoted as per specification in the Bid. The license must have been duly renewed/valid up to date and the items quoted shall be clearly highlighted (*Bid item codes marked against each item*) in the license.
- (f) Attested photocopy of the valid import license in Form 10 with Form 41 (as per Rule 122A of Drugs and Cosmetics Act), if the product is imported. The license must have been renewed /valid up to date. A copy of a valid license for the sale of Drugs imported by the firms issued by the licensing authority shall be enclosed.
- (g) The instruments such as power of attorney, resolution of board etc., authorizing an officer of the Bidder should be enclosed.
- (h) Authorization/nominating a responsible person of the Bidder to transact the business with the Bid Inviting Authority with photograph and signature in Annexure VII.

(i) Bidder should have at least 3 years market standing as a manufacturer for the items quoted in the bid.

For imported items, the quoted item should have 3 years market standing, for which bills of entry, sale invoices, etc should be submitted to establish the claim. The importing firm should have 3 years standing as importer / manufacturer of medicines in general. The manufacturer may submit his licence or MARKET STANDING CERTIFICATE to establish 3 years standing; The importer firm may submit Bills of entry, etc of same or other Surgical /Drugs to establish the market standing of the firm. The bidder shall submit valid import license for direct import of the quoted item.

- (j) Market Standing Certificate issued by the Licensing Authority / competent authorities as a Manufacturer for the product for last 3 years (Certificate should be enclosed with list of items) should be enclosed. Items quoted should be highlighted in the market standing certificate. For imported items, the quoted item should have 3 years market standing, for which bills of entry, sale invoices, etc should be submitted to establish the claim. The importing firm should have 3 years standing as importer / manufacturer of medicines in general. The manufacturer may submit his licence or MARKET STANDING CERTIFICATE to establish 3 years standing; the importer firm may submit Bills of entry, etc of same or other drugs to establish 3 years for importing the items and to establish the market standing of the firm. The MSC should not have been issued by competent authority more than 2 years old as on the last date of bid submission. The bidder shall submit valid import licence for import of the quoted item. The market standing of products containing Paracetamol 500 mg shall be accepted in tablet combination where Paracetamol 325 mg is specified. However, for all above, the firm has to submit with bid, the product permission (from the Licensing Authority) as per bid specifications of the RMSC formula.
- (k) Non-conviction Certificate issued by the Drugs Controller of the State. It should be recent and not more than one year old.

- (1) Good manufacturing practices Certificate (GMP) as per revised Schedule –'M', or WHO-GMP Certificate issued by the Licensing Authority. The GMP certificate must not be older than one year from the due date of Bid submission in the case where validity is not mentioned in the certificate. The Bidder shall also furnish an undertaking in the format given in Annexure-VII point no.8 declaring that the Bidder complies with the requirements of GMP (as per revised Schedule-'M'). The Importer should produce WHO- GMP /COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US- FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted.
- (m) Annual turnover statement for 3 years i.e., 2010-11, 2011-12 and 2012-13 or 2011-12, 2012-13 and 2013-14 in the format given in Annexure-III certified by the practicing Chartered Accountant.
- (n) Copies of the Balance Sheet and Profit and Loss Account for three years i.e. 2010-11, 2011-12 and 2012-13 or 2011-12, 2012-13 and 2013-14 duly certified by the practicing Chartered Accountant.
- (o) VAT/Sales Tax Clearance certificate (copies of latest challans), as on *31.12.2013*.
- (p) Registration with Excise Department, Govt. of India. The industries situated in excise free zones will be exempted from the registration provided they produce the copy of appropriate notification.
- (q) Undertaking (as in Annexure-VII) for embossment of logo on labels of bottles, etc as the case may be, as per conditions specified at Clause 14 herein.
- (r) Undertaking that the manufacturer has not been blacklisted, the product has not been declared as not of standard quality during last two years, it's manufacturing capacity and other details required on a format mentioned at Annexure-VII.
- (s) Details of technical personnel employed in the manufacture and testing of drugs (Employee Name, Qualification, and Experience) as enclosed in license.

- (t) List of items quoted to be shown in the Annexure-VII point number 6
- (u) A Checklist (Annexure-V) for the list of documents enclosed with their page number. The documents should be serially arranged as per Annexure-V. Every bidder will also be required to submit details of product permission of the quoted item and the desired market standing, in Annexure-VI
- (v) An undertaking that the bidder complies with all the terms, conditions, amendments (if any) of bid document to be submitted in **Annexure-VII** point no.11.
- (w) A declaration under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012 in Annexure-VII point no. 13
- (x) All copies submitted should be attested and notarized. However, scanned copies of original documents will be accepted which obviously need be notary attested.
- (y) An undertaking in Annexure-XI that the bidder whishes to get empanelled as supplier for the quoted items and has submitted the necessary fee for the same. (This is only for those who apply for empanelment also). *The bidders who have already paid empanelment fees in previous bid need* not to submit the empanelment fee for the items being quoted in this bid. However the required annexure must be submitted.
- (z) A copy of PAN issued by Income Tax Department.

6. PRICE BID -

The price bid will also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). BOQ template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bidder is liable to be rejected for this bid. Bidders are allowed to enter the bidder name and values only. The bidder should quote rate for the mentioned packing unit only.

7. OPENING OF TECHNICAL AND FINANCIAL EVALUATION

The Bid will be scrutinized by Bid evaluation committee and inspection of manufacturing unit for compliance of GMP may be carried out by technical committee. Price Bid (BOQ) of the Bidder found eligible on satisfying the criteria for technical evaluation and inspection, will only be opened.

8. **BID SECURITY**

The Bid Security shall be @ Rs. 20,000/- for each item of Drugs & Medicines quoted subject to minimum of Rs. 2.00 lacs and maximum of Rs. 5.00 Lacs. In case Bid Security submitted by the bidder is at the minimum or more but number of quoted items is more than the Bid Security submitted, the quoted items by the bidder will be counted in sequence up to the Bid Security deposited. However without minimum Bid Security the offer will not be considered at all., Bid Security will not be taken from undertakings, corporation of GoI & GoR. Further, Bid Security will be taken @ Rs. 5,000/- per item of Drugs & Medicines quoted subject to minimum of Rs. 50,000/- and maximum of Rs. 1.25 Lacs, from SSI Units of Rajasthan. They will furnish copy duly attested by gazetted officer of the registration of SSI units issued by the Director of Industries in respect of the stores for which they are registered. Duly attested copy of Acknowledgement of EM-II issued by DIC with an affidavit worth Rs.10 as per Annexure-II under preference to Industries of Rajasthan rules 1995 in respect of stores for which they are registered. (Annexure-II). In case Bid Security submitted by the bidder is at the minimum or more but number of quoted items is more than the Bid Security submitted, the quoted items by the bidder will be counted in sequence up to the number matching the Bid Security deposited. However without minimum Bid Security the offer will not be considered at all.

The Bid Security shall be paid in through separate prescribed challans (format enclosed in Annexure-I) in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country upto 18.06.2014 or through D.D. / bankers cheque in favour of M.D. RMSCL physically in the office of RMSC by 1.30 PM on 19.06.2014. Bid security Deposit in any other form will not be

accepted. Alternatively bidder may also deposit Bid document fees, Bid security and RISL processing fees by way of e-deposit, through Internet Banking by accessing RMSC website rmsc.nic.in clicking e-deposit icon following the laid down steps; Rs.25 plus applicable service tax will be the per transaction charge to be debited in respective depositor's account after successful e-deposit. Supplier should enclose the generated receipt.

The Bids submitted without sufficient Bid Security will be summarily rejected. The Bid Security will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails within specified time to sign the contract agreement or fails to furnish the performance security.

9. **OTHER CONDITIONS**

- The orders will be placed by the Managing Director or any officer designated, Rajasthan Medical Services Corporation Ltd, (hereinafter referred to as Ordering Authority).
- 2. The details of the required drugs, medicines, etc., are shown in Annexure-VIII. The quantity mentioned is only the tentative requirement and may increase or decrease as per the decision of Ordering Authority. The rates quoted should not vary with the quantum of the order or the destination. The commitment quantity for an item submitted by the bidder (in Annexure VII) shall be taken in to account and a bidder not having adequate capacity (as reflected in commitment quantity) may be technically disqualified.
- 3. Bid has been called for in the **generic names of drugs**. The Bidders should quote the rates for the generic products. The composition and strength of each product should be as per details given in **Annexure-VIII**. Any variation, if found, will result in rejection of the Bid. The products should conform to the specified standards IP/BP/USP. In case the product is not included in the said compendium, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing.
- 4. Rates (inclusive of Excise Duty, Customs duty, transportation, insurance, and any incidental charges, but exclusive of Sales tax) should be quoted for each of the required drugs, medicines etc., separately on door delivery basis according to

the unit ordered. Bid for the supply of drugs, medicines, etc. with conditions like "AT CURRENT MARKET RATES" shall not be accepted. Handling, clearing, transport charges etc., will not be paid. The delivery should be made as stipulated in the purchase order placed with successful Bidders. No quantity or cash discount should be offered.

5.

- a) To ensure sustained supply without any interruption, the Bid Inviting Authority reserves the right to fix more than one supplier to supply the requirement among the qualified Bidders
- b) Orders will be placed periodically during rate contract period based on the stock positions only. Orders will be placed with L1 firms. However in order to ensure regular supply in case of any exigency at the discretion of the Bid Inviting Authority, the orders may also be placed with the other firms, in the ascending order, L-2, L-3 and so on who have matched the L1 rates.
- c) After the conclusion of Price Bid opening, the lowest offer of the Bidder, if required will be considered for negotiations, and rate arrived after negotiations will be L-1 rate and L-1 supplier for an item of drugs/medicines for which the Bid has been invited.
- d) The Bidder who has been declared as L-1 supplier for certain item or items of drugs/medicines shall execute necessary agreement for the supply of the Bided quantity of such drugs/medicines as specified in the Bid document on depositing the required amount as performance security and on execution of the agreement, such Bidder is eligible for the placement of purchaser orders.

 Moreover, purchase order can be placed after the issue of letter of acceptance, pending the execution of agreement and issuance of rate contract for an item.
- e) RMSC will inform the L1 rate to the Bidders who qualified for Price Bid opening, through RMSC web site or e-mail; willing bidders may inform in writing their consent to match with the L-1 rate for the item of the Drugs/Medicines quoted by them and the Bidders who agree to match L1 rate, will be considered as Matched L1.

- f) The Bidder, who agrees to match L-1 rate shall furnish the breakup detail (Rate, CST, VAT etc.) of price (L-1 rate).
- g) The supplier upon receipt of the purchase order deems that the purchase orders exceeds the production capacity declared in the Bid documents and the delay would occur in executing the order, shall inform the RMSC immediately without loss of time and the purchase orders shall be returned within 7 days from the date of the order, failing which the supplier is stopped from disputing the imposition of liquidated damages, fine for the delayed supply.
- h) If the L1 supplier has failed to supply /intimated RMSC about his inability/delay in supply as per the purchase order, the required Drugs/ Medicines within the stipulated time or as the case may be, RMSC may also place purchase orders with the Matched L1 Bidder for purchase of the Drugs/Medicines, provided such matched L1 Bidders shall execute necessary agreement indicating the production capacity as specified in the Bid document on depositing the required amount. Such Bidder is eligible for the placement of purchase orders for the item or items of Drugs/Medicines quoted by them.
- i) Subject to Para (h) above, while RMSC has chosen to place purchase orders with Matched L1 supplier and there are more than one such matched L1 suppliers, then the purchase orders for the requirement of Drugs/Medicines will be placed with L-2 first on matched rates of L-1 and in case L-2 does not have the required capacity than L-3 would be considered on matched L-1 rates and the same order would be followed in case of L-3, L-4 etc.
- j) The matched L1 supplier, on placement of purchase orders, will be deemed as L-1 rate supplier for the purpose of the Bid and all provisions of the Bid document applicable to L-1 rate Bidder will apply mutatis mutandis to the matched L1 supplier.
- k) If the purchase order quantity is very less (which do not make even a normal small batch size; order quantity is less than 1 lac Tab/Cap, or less than 10,000 injections/ bottles/ tubes), the supply may be allowed in brand name to ensure

- uninterrupted sustained supply. However, the label should possess the required logogram, and the price should not appear on the label.
- 6. The rates quoted and accepted will be binding on the Bidder during validity period of the bid and any increase in the price (except increase due to Excise Duty or any other statutory taxes) will not be entertained.
- 7. No Bidder shall be allowed at any time on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by him after last date fixed for receipt of bid. Representation to make correction in the Bid documents on the ground of Clerical error, typographical error, etc., committed by the Bidders in the Bids shall not be entertained after submission of the Bids. Conditions such as "SUBJECT TO AVAILABILITY" "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the Bids of those who have given such conditions shall be treated as incomplete and accordingly the Bid will be rejected.
- 8. The rates should be quoted only for the composition stated in the Bid.
- 9. Supplies should be made directly by the bidder and not through any other agency.
- 10. The Bidder shall allow inspection of the factory at any time by a team of Experts/Officials of the Bid Inviting Authority and or of the Govt. of Rajasthan. The Bidder shall extend all facilities to the team to enable to inspect the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If a Company/Firm does not allow for any such inspection, its Bids will be rejected.

10. ACCEPTANCE OF BID

- 1. The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria.
- 2. Bid Inviting Authority reserves the right to accept or reject the Bid for the supply of all or any one or more items of the drugs Bided for in a Bid without assigning any reason.
- 3. Bid Inviting Authority, or his authorized representative (s) has the right to inspect the factories of Bidders, before, accepting the rate quoted by them, or before releasing any purchase order(s), or at any point of time during the continuance of

Bid and also has the right to reject the Bid or terminate/cancel the purchase orders issued and or not to reorder, based on adverse reports brought out during such inspections.

- 4. The acceptance of the Bids will be communicated to the successful Bidders in writing by the Bid inviting authority. Immediately after receipt of acceptance letter, the successful Bidder will be required to deposit PERFORMANCE SECURITY and agreement but not later than 15 days.
- 5. The approved rates of the successful Bidders would be valid for one year (*w.e.f* date of letter of acceptance) as Annual Rate contract, may extendable by 3 months with mutual consent.
- 6. Moreover, purchase order can be placed after the issue of letter of acceptance, pending the execution of agreement and issuance of rate contract for an item.

11. PERFORMANCE SECURITY

The Successful Bidders shall be required to pay performance Security Deposit @ 5% of the Contract value. Performance security will not be taken from undertaking, corporation of GoI & GoR.. The SSI Units of Rajasthan shall be required to pay Performance security @ 1% of the contract value.

The performance guarantee should be paid upfront in respect of each contract on or before the due date fixed by Bid inviting authority in the form of Bank Guarantee (**Performa given in Annexure XIV**) in case the amount exceeds Rs 5 Lakhs. For amount of upto 5 Lakhs it should be deposited in the form of demand draft/bankers cheque issued by a scheduled bank or may be deposited through challan annexure 1 (the validity of bank guarantee should be for a period of twenty four month from the date of issuance of Bank Guarantee) in favor of the Managing Director, Rajasthan Medical Services Corporation Ltd, Payable at Jaipur, viz. Bid inviting authority before releasing the purchase order by the ordering authority. In case L-2, L-3 and so on, bidders who have agreed to match L-1 price, then the Bid Security Deposit of L-2, L-3 and so on bidders will be converted (**Rs 20000/- per item**) into security deposit. In case of inability of L-1 bidder to supply the required quantity of drugs, in that case the L-2 and L-3 supplier (as the case may be) will be asked to supply the drugs. At the time of

placing of order these matched suppliers will be asked to deposit amount of balance security for a period of 24 month.

Performance Security shall remain valid and refunded 60 days beyond the date of completion of all contractual obligations or after 24 months from the date of issuance of letter of acceptance, whichever is later.

12. AGREEMENT

- a) The successful Bidder shall execute an agreement on a non-judicial stamp paper of value mentioned in the Acceptance Letter (stamp duty to be paid by the Bidder) within 15 days from the date of the intimation letter of interest by the Bid Inviting Authority, viz., the Managing Director, Rajasthan Medical Services Corporation Ltd. The Specimen form of agreement is available in Annexure-IV, failing to submission of performance security and execution of agreement within 15 days as stipulated, will result in forfeiture of Bid Security Deposit & other consequential action.
- b) The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any person or persons whatsoever.
- c) All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or left at the premises, places of business or abode.

13. SUPPLY CONDITIONS

- Purchase orders along with the delivery destinations will be placed on the successful Bidder at the discretion of the Ordering Authority. Drugs and Medicines will be supplied at 34 District drug ware houses and 6 Medical College Warehouses of Rajasthan.
- 2. The supplier shall supply the entire ordered quantity before the end of 60 days from the date of issue of purchase order at the destinations mentioned in the purchase order, if the above day happened to be a holiday for RMSC, the supply should be completed by 5.00 p.m. on the next working day. For drug items requiring sterility test and imported ones, the supply period will be 75 days from the date of issue of purchase order.

- 3. All supplies will be scheduled for the period from the date of purchase order till the completion of the bid in installments, as may be stipulated in the purchase order.
- 4. Shelf Life: The labeled shelf life of drugs supplied should be not less than the period mentioned against each item in list of Drugs (Annexure-VIII). The remaining shelf life of the drugs at the time of delivery should not be less than ¾ of the labeled shelf life. Only those bidders shall quote who can manufacture and supply the product with the required shelf life. The product of labeled shelf life lesser than required shelf life will not be accepted. The product should not have such storage condition requiring it to be stored below 2°C.

Quality Assurance: The supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of specifications and related documents (b) meet the recognized standards for safety, efficacy and quality; (c) are fit for the purpose made; (d) are free from defects in workmanship and in materials and (e) the product has been manufactured as per cGMP included in Schedule M of Drugs & Cosmetic Rules.

In case of imported items the remaining shelf life of 60% or more may be accepted with an undertaking that the firm will replace the unused expired stores with fresh goods. However, firms supplying drugs with remaining shelf life of 75% or more need not submit such undertaking.

- 5. The protocol of the tests should include the requirements given in I.P for tablets and those required specifically for the product specifications. The Bidder must submit its Test/ Analysis Report for every batch of drug along with invoice. In case of failure on the part of the supplier to furnish such report, the batch of drugs will be returned back to the supplier and he is bound to replenish the same with approved laboratory test report. The supplier shall provide the validation data of the analytical procedure used for assaying the components and shall provide the protocols of the tests applied.
- 6. The Drugs and medicines supplied by the successful Bidder shall be of the best quality and shall comply with the specification, stipulations and conditions specified in the Bid documents.

- 7. If supplies are not fully completed in 60 days from the date of the Purchase Order (75 days for drugs of the category of serum, vaccine, enzymes, blood grouping reagents, biological products, powder for injections and imported drugs), the provisions of liquidated damages of Bid conditions will come into force. The Supplier should supply the drugs at the Warehouse specified in the Purchase Order and if the drugs supplied at a designated places other than those specified in the Purchase Order, transports charges will be recovered from the supplier.
- 8. If the supplier fails to execute at least 50% of the quantity mentioned in single purchase order and such part supply continues for three consecutive Purchase orders, then the supplier will be ineligible to participate in any of the Bids for particular items of drugs/medicines for a period of one year immediately succeeding year in which supplier has been placed Purchase order.
- 9. If the Bidder fails to execute the supply within the stipulated time, the ordering authority is at liberty to make alternative purchase of the items of drugs and medicines for which the Purchase orders have been placed from any other sources (such as Public Sector undertakings at their rates, empanelled bidders, and bidders who have been technically qualified in the said bid) or in the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the Ordering Authority/Bid inviting authority has every right to recover the cost and impose penalty as mentioned in Clause 19, apart from terminating the contract for the default.
- 10. The order stands cancelled after the expiration of delivery period, and if the extension is not granted with or without liquidated damages. Apart from risk/alternate purchase action, the Bidder shall also suffer forfeiture of the performance security and shall invite other penal action like blacklisting/Debarring disqualification from participating in present and future Bids of Bid Inviting Authority/ordering authority. . (As per guidelines for blacklisting/debarring at annexure- IX including amendment)
- 11. It shall be the responsibility of the supplier for any shortage/damage at the time of receipt at the designated places.

- 12. If at any time the Bidder has, in the opinion of the ordering authority, delayed in making any supply by reasons of any riots, mutinies, wars, fire. storm, tempest or other exceptional cause on a specific request made by the Bidder within 7 days from the date of such incident, the time for making supply may be extended by the ordering authority at its discretion for such period as may be considered reasonable. The exceptional causes do not include the scarcity of raw material, Power cut, labour disputes.
- 13. The supplier shall not be in any way interested in or concerned directly or indirectly with, any of the officers, subordinates or servants of the Bid Inviting Authority in any trade or business or transactions nor shall the supplier give or pay promise to give or pay any such officers, subordinates or servants directly or indirectly any money or fee or other considerations under designation of "Customs" or otherwise, nor shall the supplier permit any person or persons whom so ever to interfere in the management or performance hereof under the power of attorney or otherwise without the prior consent in writing of the Bidder Inviting Authority.
- 14. If the supplier, or any of its approved items gets debarred/banned/blacklisted in any states after entering into agreement with RMSC, it shall be the responsibility of the supplier to inform RMSC without any delay about the same.
- 15. The supplier of sevoflurane anesthetic (code no. 491) shall install vaporizers on loan basis free of cost, in required numbers, as per the need of the Healthcare facilities/institutions.

14. <u>LOGOGRAMS / Markings</u>

Logogram means, wherever the context occurs, the design as specified below:-

DESIGNS FOR LOGORAMS

INJECTIONS

Injection in ampoule form should be supplied in Double constructed neck ampoules with the lable bearing the words "Rajasthan Govt. Supply- Not for sale নি:যুক্ক বিরেশ हेतु, QC – Passed" overprinted and the following logogram which will distinguish from the normal trade packing. Name of drug should be printed in English and Hindi

languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



The vials should be supplied with aluminum seals containing the following logogram:



LIQUIDS

Liquid preparations should be in bottles with pilfer-proof caps bearing the following logogram:



The top of the cap and the label to be affixed on the containers should bear a distint colour different from the colour of the label of the trade packs and they should be overprinted in red colour with the words "Rajasthan Govt. Supply- Not for Sale नि:शुल्क वितरण हेतु, QC – Passed" and the logogram. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



OINTMENTS & CREAMS

Ointments & Creams should be supplied in tubes bearing the following logograms and the words "Rajasthan Govt. supply- Not for sale নি:যুক্ক বিনেশ हेतु, QC – Passed" overprinted. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



TABLETS & CAPSULES

Tablets and Capsules should be supplied in Strips or Blisters or as mentioned in the list of items for bid. The strip, etc, should bear the following logograms and the words "Rajasthan Govt. supply- Not for sale নি:যুক্ত वितरण हेतु, QC – Passed" overprinted. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



SPECIMEN LABEL FOR OUTER CARTON

SHALL BE OF DIFFERENT COLOURS FOR DIFFERENT CLASS OF DRUGS

RAJASTHAN GOVT. SUPPLY NOT FOR SALE

(Name of Drugs etc.)

CONSTITUENTS	OF

Name of the Drug, Manufactured by, Batch no Mfg.Date, Exp. Date, Quantity/Kit

Net. Weight:....Kg

Manufactured by/Assembled by

The name of the drug shall be mentioned in Hindi and English and should be legible and be printed more prominently. A uniform colour theme and artwork will be necessary. Apart from this "For Govt. of Rajasthan – Not for Sale निःशुल्क वितरण हेतु, QC – Passed" along with logo of RMSCL will be printed on each strip/label of the bottle. The storage directions should be clear, legible and preferably with yellow highlighted background.

- 1. Bids for the supply for Drugs and medicines etc., shall be considered only if the Bidder gives undertaking in his Bid that the supply will be prepared and packed with the logogram printed on the strips of tablets and capsules and labels of bottles, ampoules and vials etc., as per the design mentioned above.
- 2. All tablets and capsules have to be supplied in standard packing in aluminum strip or blisters with aluminium foil back with printed logogram and shall also conform to schedule P1 of the Drugs & Cosmetics Act & Rules wherever it applies. Affixing of stickers and rubber stamps shall not be accepted.
- 3. Labels of Vials, Ampoules and Bottles containing the items Bided for should also carry the logogram.
- 4. Failure to supply Drugs etc., with the logogram will be treated as breach of the terms of agreement and liquidated damages will be deducted from bills payable as per conditions in Clause 18.2 Bidders who are not willing to agree to conditions above will be summarily rejected.
- 5. In case of imported drugs affixing rubber stamp on the original label is allowed with indelible ink on inner most and outer packing.

15. PACKING

- 1. The item shall be supplied in the package schedule given below and the package shall carry the logogram specified in clause -14. The labeling of different packages should be as specified below. The packing in each carton shall be strictly as per the specification mentioned. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties.
- 2. The pediatric drops should always be supplied with dropper. A measuring cap with suitable markings must be provided for other paediatric oral liquid preparations.
- 3. The labels in the case of injectables should clearly indicate whether the preparations are meant for IV, IM, SC, etc.
- 4. Injection vials should have flip off seals.
- 5. All plastic containers should be made of virgin grade plastic.
- 6. The name of the drug should be printed in clearly legible bold letters (It is advisable that the colour of font be different from other printed matter to make the name highly conspicuous.
- 7. It should be ensured that only first hand fresh packaging material of uniform size is used for packing. All packaging must be properly sealed and temper proof.
- 8. All packing containers should strictly conform to the specifications prescribed in the relevant pharmacopoeia/Act.
- 9. Packing should be able to prevent damages or deterioration during transit.
- 10. In the event of items supplied found to be not as per specifications in respect of their packing, the Ordering Authority is at liberty to make alternative purchase of the item for which the purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier. In such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 18.2 and 19.

I. SCHEDULE FOR PACKAGING OF DRUGS AND MEDICINES GENERAL SPECIFICATIONS

No corrugate package should weigh over 15 kgs (i.e. product + inner carton + corrugated box).

All items should be packed only in first hand strong boxes only.

Every corrugated box should preferably be of single joint and not more than two joints.

Every box should be stitched using pairs of metal pins with an interval of two inches between each pair.

The flaps should uniform meet but should not overlap each other. The flap when turned by 45-60 should not crack.

Every box should be sealed with gum tape running along the top and lower opening.

CARRY STRAP:

Every box should be strapped with two parallel nylon carry straps (they should intersect.)

LABEL:

Every corrugated box should carry a large outer label clearly indicating that the product is for "Rajasthan Govt. Supply-Not for Sale".

The Product label on the cartoon should be large, at least 15 cms x 10 cms dimension. It should carry the correct technical name, strength or the product, date of manufacturing, date of expiry quantity packed and net weight of the box.

OTHERS:

NO box should contain mixed products or mixed batches of the same product.

II. SPECIFICATION FOR CORRUGATED BOXES HOLDING TABLETS/CAPSULES/PESSARIES

1. The total weight of the box should be approx of 7-8 Kgs.

III. SPECIFIATION FOR LARGE VOLUME BOTTLE i.e., ABOVE 100 ml AND BELOW 1 LIT.

1. All these bottles should be packed only in single row with partition between each and also with top and bottom pad of 3 ply.

IV. SPECIFICATION FOR IV FLUIDS

Each corrugated box may carry maximum of only 24 bottles of 500 ml in a single row or 50 bottles of 100 ml in 2 rows with individual sealed polythene cover and centre partition pad, top and bottom pads of 3 ply.

V. SPECIFICATION FOR LIQUID ORALS

100 bottles of 50 ml or 60 ml may be packed in a single corrugated in 2 rows with top, bottom and centre pad of 3 ply.

50 bottles of 100 ml - 120 ml may be packed in a similar manner in a single corrugated box.

If the bottles are not packed in individual carton, 3 ply partition should be provided between each bottle. The measuring device should be packed individually.

VI. SPECIFICATION FOR OINTMENT/CREAM/GELS PACKED IN TUBES:

No corrugated box should weigh more than 7-8 Kgs.

Every Ointment/Cream/Gel tube should be individually packed in carton and then packed in 20's in a grey board box, which may be packed in a corrugated box.

VII. SPECIFICATIONS FOR INJECTION (IN VIALS AND AMPOULES)

Vials may be packed in corrugated boxes weighing upto 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 Kgs.

In the case of 10 ml Ampoules or 50 ampoules may be packed in a grey board box. Multiples of grey board boxes packed in CB. In case of ampoules larger than 10 ml only 25 ampoules may be packed in a grey board box with partition.

If the vial is packed in individual cartoon, there is no necessity for grey board box packing. The individual cartoon may be packed as such in the CB with centre pad.

In case of ampoules every grey board box should carry 5 amps alongwith Cutters placed in a polythene bag.

Vials of eye and ear drops should be packed in a individual cartoon with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a grey board box.

VIII. SPECIFICATION FOR ORS

The sachets should be of Aluminium Foil laminated with glassin or heat sealable plastic film, Outer paper may contain label information.

50 sachets may be packed in grey board boxes and 10 grey board boxes in a C.B.

IX. LYSOL

Not more than four 5 liters cans may be packed in a single Box.

16. QUALITY TESTING

- 1. Sampling of supplies from each batch will be done at the point of supply or distribution/storage points for testing. (The samples would be sent to different empanelled laboratories for testing by the ordering authority after coding). The RMSC will deduct a sum of 1.5% from the amount of bill payable to supplier on account of handling and testing charges.
- 2. The Drugs shall have the active ingredients within the permissible level throughout the shelf life period of the drug. The samples may also be drawn periodically during the shelf life period. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirements shall render the relevant batches liable to be rejected. If the sample is declared to be Not of Standard Quality or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.
- 3. In the event of the samples of the Drugs and medicines supplied failing quality tests or found to be not as per specification the ordering authority is at liberty to make alternative purchase of items of drugs and medicines for which the Purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 19.
- 4. The supplier shall furnish to the purchaser the evidence of bio-availability and/or bio-equivalence for certain critical drugs when asked for. If there is any problem in the field the B.M.R/B.P.R for the particular batch shall also be supplied when demanded.
- 5. The products should conform to the standards of IP/BP / USP as the case may be. In case the product is not included in the said compendium, the supplier, upon award of the contract, must provide the reference standards and testing protocols

for quality control testing. For imported drugs respective countries pharmacopeia standards shall be acceptable (even if the product is official in IP)

17. PAYMENT PROVISIONS

- 1. No advance payment towards costs of drugs, medicines etc., will be made to the Bidder.
- 2. On receipt of the prescribed consolidated invoice duly stamped and signed by authorized signatory and analytical laboratory report regarding quality, the payment would be made in 30 days. (Annexure- XIII & XIV)
- 3. The in charge of district drug warehouse (DDW) will acknowledge the drugs received & ensure entry in e- Aushdhi software online.
- 4. All bills/ Invoices should be raised in duplicate and in the case of excisable Drugs and Medicines; the bills should be drawn as per Central Excise Rules in the name of the authority as may be designated. The supplier will deliver following document at the time of delivery at DDW.
 - a. In house test report of drug.
 - b. The challan / invoice copy pertaining to DDW
- 5. Payments for supply will be considered only after supply of 70% of items of Drugs ordered in the Purchase Order .However, the payment will be released only for the quantity in case of which the quality test report from approved test laboratories of RMSC has been received and found of standard quality.
- 6. If at any time during the period of contract, the price of Bided items is reduced or brought down by any law or Act of the Central or State Government or by the Bidder himself, the Bidder shall be bound to inform ordering authority immediately about it. Ordering authority empowered to unilaterally effect such reduction as is necessary in rates in case the Bidder fails to notify or fails to agree for such reduction of rates.

In case the price of a drug fixed by NPPA (Govt of India) under applicable DPCO is less than the RMSC contract price, the supplier shall be bound to make the supplies of such items at price fixed by the Govt.

7(a) In case of any enhancement in Excise Duty due to notification of the Government after the date of submission of Bids and during the Bid period, the quantum of additional excise duty so levied will be allowed to be charged extra as a separate

item without any change in the basic of the price structure price of the Drugs approved under the Bid. For claiming the additional cost on account of the increase in Excise Duty, the Bidder should produce a letter from the concerned Excise authorities for having paid additional Excise Duty on the goods supplied to ordering authority and also must claim the same in the invoice separately.

Similarly if there is any reduction in the rate of essential drug, as notified by the Govt., after the date of submission of Bid, the quantum of the price to the extent of reduction of essential drug will be deducted without any change in the basic price of the price structure of the drugs approved under the Bid.

- 7(b) In case of successful bidder has been enjoying excise duty exemption on any criteria of Turnover etc., such bidder will not be allowed to claim excise duty at later point of time, during the tenure of contract, when the excise duty is chargeable on goods manufactured.
 - 8. (i) If the supplier requires an extension in time for completion of contractual supply, on account of occurrence of any hindrance he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of completion of supply.
 - (ii) The purchase Officer may extend the delivery period with or without liquidated damages in case they are satisfied that the delay in the supply of goods is on account of hindrances. Reasons shall be recorded.
 - (iii) **Extension in delivery period:-** In case of extension in the delivery period with liquidated damages the recovery shall be made on the basis of following percentages of value of stores which the Bidder has failed to supply:-
 - a) Delay upto one fourth period of the prescribed delivery period; 2.5%
 - b) Delay exceeding one fourth but not exceeding half of the prescribed delivery period; 5%
 - c) Delay exceeding half but not exceeding three fourth of the prescribed delivery period; 7.5%
 - d) Delay exceeding three fourth of the prescribed delivery period; 10%
 - **Note 1:-** Fraction of a day in reckoning period of delay in supplies shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.

- Note 2:- If a supplier seeks extension in supply period beyond two times the time indicated in purchase order, the supply period shall be extended with the condition that if the rate received in new bid(s) invited are lower than the rate contract in operation, then the supplier shall be entitled to the lower rates so received.
- 9. If, at any time during the continuance of this Agreement, the Supplier has, in the opinion of the Purchaser, delayed in making any supply ordered, by the reasons of any riots, mutinies, ears, fire, storm, tempest or other exceptional cause, on a specific request made by the Supplier, the time for effecting delivery may be extended by the Purchaser surely at his discretion for such period as may be considered reasonable by the Purchaser. No further representation from the Supplier will be entertained on this account.

18. <u>DEDUCTION IN PAYMENTS:</u>

- 1. If the supply is received in damaged conditions it shall not be accepted.
- 2. All the Bidder are required to supply the product with logogram and with prescribed packing specification. If there is any deviation in these Bid conditions a separate damages will be levied @ 2% irrespective of the ordering authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause **No.15.10**.

19. OUALTIY CONTROL DEDUCTION&OTHER PENALTIES:

- 1. If the successful Bidder fails to execute the agreement and/or to deposit the required performance security within the time specified or withdraws his Bid after the intimation of the acceptance of his Bid has been sent to him or owing to any other reasons, he is unable to undertake the contract, his contract will be cancelled and the Bid security Deposit deposited by him along with his Bid, shall stand forfeited by the Bid Inviting Authority and he will also be liable for all damages sustained by the Bid Inviting Authority apart from blacklisting/ debarring at annexure IX including amendment)
- 2. If the samples drawn from supplies do not conform to statutory standards, the supplier will be liable for relevant action under the existing laws and the entire stock in such batch should be taken back by the supplier within a period of 30 days from the issue of letter from ordering authority the information of which

may be communicated by e- mail. The stock shall be taken back at the expense of the supplier. Ordering authority has the right to destroy such NOT OF STANDARD DRUGS IF THE SUPPLIER does not take back the goods within the stipulated time. Ordering authority will arrange to destroy the NOT OF STANDARD drugs within 90 days after the expiry of 30 days mentioned above, without further notice, and shall also collect demurrage charge calculated @ 2% per week on the value of the drugs rejected till such destruction. The supplier shall replace the stock of NOSQ goods with fresh goods upon intimation to do so by the ordering authority.

- 3. The supplier will not be entitled to any payment whatsoever for Items of drugs found to be of NOT OF STANDARD QUALITY whether consumed or not consumed and the ordering authority is entitled to deduct the cost of such batch of drugs from the any amount payable to the Bidder. On the basis of nature of failure, the product/supplier will be moved for Black Listing. (As per guidelines for blacklisting/ debarring at annexure IX including amendment)
- 4. For supply of drugs of NOT OF STANDARD QUALITY the respective Drugs Controller will be informed for initiating necessary action on the supplier and that the report of product shall be sent to the committee for appropriate action including blacklisting. (As per guidelines for blacklisting/ debarring at annexure IX including amendment)
- 5. The decision of the ordering authority or any Officer authorized by him as to the quality of the supplied drugs, medicines etc., shall be final and binding.
- 6. Ordering Authority will be at liberty to terminate without assigning any reasons thereof the contract either wholly or in part on 30 days notice. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.
- 7. For infringement of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the ordering authority, and the supplier shall be liable for all losses sustained by the ordering authority, in consequence of the termination which may be recovered personally from the supplier or from his properties, as per rules.
- 8. Non performance of any contract provisions shall be examine and may disqualify the firm to participate in the future Bids.

- 9. In the event of making ALTERNATIVE PURCHASE, as specified in Clause 13.10, Clause 15.10 and in Clause 16.3 the penalty will be imposed on supplier apart from forfeiture of Security Deposit. The excess expenditure over and above contracted process incurred by the ordering authority in making such purchases from any other sources or from the open market or from any other Bidder who has quoted higher rates and other losses sustained in the process, shall be recovered from the performance security or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier.
- 10. In all the above conditions, the decision of the Bid Inviting Authority, viz Managing Director, Rajasthan Medical Services Corporation Ltd, would be final and binding; in case of any dispute regarding all cases under Bid procedure or in any other non-ordinary situation and would be acceptable to all.
- 11. All litigations related to the supplier for any defaults will be done by Bid Inviting Authority and his decision will be final and binding.

20. EMPANELMENT OF FIRMS

RMSC invites Applications from eligible firms for Empanelment for supply of Drugs & Medicines mentioned in Annexure- VIII for one year. The empanelment would entitle a firm to participate in RMSC for limited bids. Such situations may normally arise when the open bid for a Drugs & Medicines fails and there is an urgency to purchase it, or when the L-1 bidder has fail to supply, or the rate contract of an item ceases to exist for any reason. The Bidder has to submit an undertaking in the format given at Annexure-XI.

The empanelment can be renewed for the next one year term on payment of the empanelment fee as applicable at the time of renewal.

21. SAVING CLAUSE

No suit, prosecution or any legal proceedings shall lie against Bid Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of Bid.

22. JURISDICTION

In the event of any dispute arising out of the Bid or orders such dispute would be subject to the jurisdiction of the Courts of Jaipur or Honorable High Court (Jaipur Bench **only**).

23. CORRECTION OF ARITHMETIC ERRORS:

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

- (i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;
- (ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.
- (iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.

If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

24. PROCURING ENTITY'S RIGHT TO VARY QUANTITY:

(i) At the time of award of contract, the quantity of Drugs, originally specified in the bidding documents may be increased or decreased. There will not be any minimum quantity guaranteed against bid quantity. The bid quantity is only indicative. Actual purchase can be more or less than the bid quantity based on actual consumption in the hospitals during Rate Contract period.

The supplier shall submit the supply commitment quantity" in Annexure **VII at point no. 3** which will be used for the cases where the actual purchase quantity tends to increase substantially from the bid quantity.

- (ii) If the procuring entity does not procure any subject matter of procurement or procures less than the quantity specified in the bidding documents due to change in circumstances, the bidder shall not be entitled for any claim or compensation except otherwise provided in the conditions of contract.
- (iii) However a bidder is bound to supply up to quantity indicated in bid document, considering the total production capacity & capacity dedicated to RMSC. Moreover, the actual purchases beyond Bid quantity may be made keeping in view the supply commitment of bidder to corporation.

25. <u>DIVIDING QUANTITIES AMONG MORE THAN ONE BIDDER AT (IN CASE OF PROCUREMENT OF GOODS):</u>

As a general rule all the quantities of the subject matter of procurement shall be procured from the bidder, whose bid is accepted and declared successful L-1 bidder. However, when the quantity of drugs the subject matter of procurement is very large may not be in the capacity of the bidder, whose bid is accepted, to deliver the entire quantity of drugs or when it is considered that the drugs being of critical and vital nature, in such cases, the quantity of drugs may be divided between the bidders, whose bid are accepted and the second lowest bidder or even more bidders in that order.

26. GRIEVANCE REDRESSAL DURING PROCUREMENT PROCESS:

The Designation and address of the First Appellate Authority is Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan.

The Designation and address of the Second Appellate Authority is Principal Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan and Chairman, RMSCL.

i. Filling an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:

Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

- ii. The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.
- iii. If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of receipt of the order passed by the First Appellate Authority, as the case may be.

iv. Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

- (a) Determination of need of procurement;
- (b) Provision limiting participation of Bidders in the Bid process; (c) The decision of whether or not to enter into negotiations;
- (d) Cancellation of a procurement process;
- (e) Applicability of the provisions of confidentiality.

v. Form of Appeal

(a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.

- (b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.
- (c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.

vi. Fee for filling appeal

- (a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.
- (b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

vii. Procedure for disposal of appeal

- (a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.
- (b) On the date fixed for hearing, the First Appellate Authority or Second Appellate

Authority, as the case may be, shall,-

- (i) Hear all the parties to appeal present before him; and
- (ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.
- (c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.
- (d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

27. <u>COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:</u>

Any person participating in a procurement process shall-

- a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;
- b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;
- c) Not indulge in any collusion, Bid rigging or any-competitive behaviour to impair the transparency, fairness and progress of the procurement process;
- d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;
- e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;
- f) Not obstruct any investigation or audit of a procurement process;
- g) Disclose conflict of interest, if any; and
- h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest.

A Conflict of interest is considered to be a situation in which a party has inter4ests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.

- I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:
- a. Have controlling partners/shareholders in common; or
- b. Receive or have received any direct or indirect subsidy from any of them; or

- c. Have the same legal representative for purposes of the Bid; or
- d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or
- e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or
- f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or
- g. Bidder or any of its affiliates has been hired (or is proposed to be hired0 by the Procuring Entity as engineer-in0chage/ consultant for the contract.

28. FALL CLAUSE

The prices under a rate contract shall be subject to price fall clause. If the rate contract holder quotes / reduces its price to render similar goods, works or services at a price lower than the rate contract price to anyone in the State at any time during the currency of the rate contract, the rate contract price shall be automatically reduced with effect from the date of reducing or quoting lower price, for all delivery of the subject matter of procurement under that rate contract and the rate contract shall be amended accordingly. The firms holding parallel rate contracts shall also be given opportunity to reduce their price by notifying them the reduced price giving them fifteen days time to intimate their acceptance to the revised price. Similarly, if a parallel rate contract holding firm reduces its price during currency of the rate contract, its reduced price shall be conveyed to other parallel rate contract holding firms and the original rate contract holding firm for corresponding reduction in their prices. If any rate contract holding firm does not agree to the reduced price, further transaction with it, shall not be conducted.

Managing Director
Rajasthan Medical Services Corporation

5
3
*
S
(D)
ш

Customer Copy

						ANNEXU	
Acknowledgement	Address for communication	Name of the Depositor	1000 * 1000 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100 * 100	Mobile No. Cash Deposit: comination Topo *	Supplier Name Tender Ref. No. Type of Deposit fees/Others	Branch Institute Name Institute ID	AUTION : USE "F
For Bank use only Cashier/Officer		itor	Total fee payable ₹	Cheque Deposit: Chq No Date of Chq Name of Bank ₹ Ps	e out of	Rajasthan Medical Services Corporation, Jaipur RMSCJ - A/c No. 2246002100024414 Date of Deposit	AUTION: USE "FCMBR" MENU OPTION IN FINACLE INSTEAD OF "TM" Bank Copy punjab national bank DIST. NO.
Acknowledgement	Address for communication	Name of the Depositor	500 * 100 * 100 * 20 * 20 * 10 * Total Amount (in words): ₹	Mobile No. Cash Deposit: Denomination 1000 *	Supplier Name Tender Ref. No. Type of Deposit Gees/Others	Institute Name Institute ID	7
	unication	sitor		Chequ ₹ Ps Chq No	E SUPPLIER Select any one out of fees/Others	Rajasthan Med	punjab i
For Bank use only			Total fcc payable ₹ Commission ₹ Total amount ₹	e Deposit: Date of Chq	Select any one out of - Tender Fees/EMD/SD/ Tender Processing fees/Others	RMSCJ - A/c No. 2246002100024414 Date of Deposit	njab national bank
Cas			0 0 0	Name of Bank	DD MM	Corporation, 46002100024	
Cashier/Office			3 1 1	74	rocessing	Jaipur 414	Customer Copy

0 0

Ps

Cashier/Officer

44

Format of Affidavit (On Non Judicial Stamp Paper of Rs. 10/-)

I		S/c)		Age		.Yrs		
residing	at			Prop	rietor/Pa	rtner/]	Director		of
M/s	do	hereby s	olemnly	affirm a	and decla	re tha	t:		
(a) My/C	Our above no	ted enter	rprises N	/I/s				has b	een
issued a	cknowledger	nent of	Entrepre	eneurial	Memor	andun	n Part-II	l by	the
Districts	Industries	Center			The	ackno	wledgem	ent	No.
is		.dated		and	has issu	ied fo	r Manuf	acture	of
following	g items.								
(i) (ii) (iii) (iv) (v) (b) My/C	Our above no	oted ackr	nowledge	ement of	f Entrep	reneur	rial Mem	noranc	lum
Part-II ha	as not been c	ancelled	or with	lrawn by	y the Inc	lustrie	s Depart	ment	and
that the e	nterprise is r	egularly 1	manufac	turing th	e above	items.			
(c) My/C	Our enterprise	e is havi	ng all th	e requis	site plan	t and	machine	ry and	d is
fully equi	ipped to man	ufacture	the abov	e noted	items.				
Place			VERIFI	Autho	orized Si Star		orietor/Di ry with R I date		
			S	5/o		Aş	ged		Yrs
at	e are true an	d correct	verify at to the	nd confi	rm that t	he cor			
DEPONE	Z1 N I								

ANNEXURE-III Ref. Clause No. 5 (m)

ANNUAL TURN OVER STATEMENT

	and medicines including Surgical and	ne Annual Turnover (<i>for arugs</i>	1.				
	usiness)	В	sutures				
	for the past three year		M/s				
	atement is true and correct.	n below and certified that the st	are giver				
	Turnover in Lakhs (Rs)	Years	S.No.				
		2010-11	1				
		2011-12	2				
		2012-13	3				
akhs	Rs. I	Total					

<u>OR</u>

Rs.

Average turnover per annual

S.No.	Years	Turnover	in Lakhs (Rs)
1	2011-12		
2	2012-13		
3	2013-14		
	Total	Rs.	Lakhs
Ave	rage turnover per annual	Rs.	Lakhs

Date:	Signature of Auditor/
	Chartered Accountant
Seal:	(Name in Capital)

Lakhs

AGREEMENT

This Dee	d of Agreemen	t is made on this _				day
of						
		2014	by	M/s		
represent	ed by its Prop	rietor/Managing p	artner/N	Managin	g Director h	aving its
Registere	ed .	O	ffice			at
					and its Facto	ory
Premises						at
(hereinaf	ter referred to	as "Supplier" whi	ch term	shall ii	nclude its su	ccessors,
represent	atives, heirs, e	executors and add	ministra	ators un	less exclude	d by the
Contract)	on one part	and Rajasthan I	Medical	l Servic	es Corporat	tion Ltd,
represent	ed by its Execu	itive Director (P) h	aving i	s office	at Swasthya	Bhawan,
Tilak Ma	arg, C-Scheme	, Jaipur (hereinaf	ter refe	erred to	as "The Pu	ırchaser"
which ter	m shall includ	e its successors, re	present	tatives, e	executors ass	signs and
administr	ator unless exc	luded by the Contr	act) on	the othe	r part.	
W	here as the Sup	oplier has agreed to	o suppl	y to the	Purchaser, t	he Drugs
and Med	icines with spe	cifications mention	ned in 1	the Sche	dule attache	d here to
at the pi	rices noted the	ere in and in the	manne	er and	under the te	erms and
condition	s here in after	mentioned and v	where a	s the Su	applier has	deposited
with	the	Purchaser		a	sum	of
Rs						_(Rupees
only) as	Performance S	Security for the d	ue and	faithful	performanc	e of this
Agreeme	nt, to be forfe	eited in the even	t of th	e Suppl	ier failing	duly and
faithfully	to perform it.	Now these presen	ts witne	ess that	for carrying	duly and
faithfully	to perform it.	Now these presen	nts witn	ness that	for carrying	g out the
said Agre	eement in this b	pehalf into execution	on the S	Supplier	and the Puro	chaser do
hereby m	nutually covena	ant, declare, contra	ct and	agree e	ach of them	with the
other of t	hem in the man	ner following, that	t is to sa	ay,		

- 1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation, the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.
- 2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.

(b)	This	Agreen	nent	shall	be	deemed	to	have	come	into	force
with	effec	t from	the	date	of	issuance	e oj	f lette	er of	ассер	otance
			an	d it sh	all re	emain in f	force	e upto			·

(c) The Bid quantity noted against each item in the schedule attached hereto indicates only the probable total requirements of the Purchaser in respect of each item for the Agreement Period indicated in Clause (b) Above. This quantity may increase or decrease at the discretion of the Purchaser. The Supplier shall make supplies of the Drugs and Medicines on the basis of the Purchaser Orders placed on him from time to time by the ordering Authorities of the purchaser specifying the quantities required to be supplied required to be supplied at the specific location in the state of Rajasthan.

TERMINATION OF CONTRACT ON BREACH OF CONDITION

- 1 (a) In case the Supplier fails or neglects or refuse to faithfully perform any of the Covenants on his part herein contained, it shall be lawful for the Purchaser to forfeit the amount deposited by the Supplier as PERFORMANCE SECURITY and cancel the Contract.
 - (b) In case the Supplier fails, neglects, or refuse to observe, perform, fulfill and keep, all or any one or more or any part of any one of the Covenants, stipulation and provisions herein contained, it shall be lawful for the Purchaser on any such failure, neglect or refusal, to put an end to this Agreement and thereupon every article, cause and thing herein contained on the part of the Purchaser shall cease and be void, and in case of any damage, loss, expenses,

difference in cost or other moneys from out of any moneys for the time being payable to the Supplier under this and/or any other Contract and in case such last mentioned moneys are insufficient to cover all such damages, losses, expenses, difference in cost and other moneys as aforesaid, it shall be lawful for the Purchaser to appropriate the Performance Security made by the Supplier as herein before mentioned to reimburse all such damages, losses, expenses, difference in cost and other money as the Purchaser shall have sustained, incurred or been put to by reason of the Supplier having been guilty of any such failure, negligence or refusal as aforesaid or other breach in the performance of this Contract.

- (c) If at any time during the course of the Contract, it is found that any information furnished by the Supplier to the Purchaser, either in his Bid or otherwise, is false, the Purchaser may put an end to the Contract/Agreement wholly or in part and thereupon the provisions of Clause (a) above shall apply.
- 2 The Purchaser reserves the right to terminate without assigning any reasons therefore the Contract/Agreement either wholly or in part without any notice to the Supplier. The Supplier will not be entitled for any compensation whatsoever in respect of such termination of the Contract/Agreement by the Purchaser.

NOTICE ETC, IN WRITING

3 All Certificates or Notice or orders for time or for extra, varied or altered supplies which are to be the subject of extra or varied charges whether so described in the Agreement or not, shall be in writing, and unless in writing, shall not be valid, biding or be of any effect whatsoever.

SUPPLIERS NOT HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATES

4 The Supplier shall not be in any way interested in or concerned directly or indirectly with, any of the Officers, Subordinate or Servants of the Purchaser. In any trade, business or transactions nor shall the Supplier give or pay or promise to give or pay any such Officer, Subordinate or Servant directly or indirectly any money or fee or other consideration under designation of "Custom" or otherwise; nor shall the Supplier permit any person or persons whomsoever to interfere in the management or performance hereof under

power of attorney or otherwise without the consent in writing the consent in writing of the Purchaser obtained in first hand.

BANKRUPTCY OF THE SUPPLIER

5 In case the Supplier at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of bankruptcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the Purchaser to put an end to the Agreement, and thereupon every article, clause and thing herein contained to be operative on the part of the Purchaser, shall cease and be void and the Purchaser shall have all the rights and remedies given to him under the preceding clauses.

SERVING OF NOTICE ON SUPPLIER

- 6 All notice or communication relating to or arising out of this Agreement or any of the terms thereof shall be considered duly served on or given to the Supplier if delivered to him or left at his premises, place of business or abode.
- 7 And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any of clause herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of the Managing Director, Rajasthan Medical Services Corporation Ltd in the matter shall be final and binding.
- 8 All disputes arising out of this agreement and all questions relating to the interpretation of this agreement shall be decide by the Govt. and the decision of the Govt. shall be final.

SUPPLIER

EXECUTIVE DIRECTOR (P), RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

Witness (Signature, Name & Address)

1. 1. 2. 2.

ANNEXURE – V Ref. Clause No. 5 (u)

Check List

Section	Details of	Document Type	Yes/No
	requirement		If Yes
			Page No.
A	BID SECURITY	Challan/DD/ e–deposit generated receipt of	1 age 110.
	DEPOSIT, RISL	Bid Security Deposit, bid fee and RISL fee and	
	Fess, Bid	SSI certificate for exemption with Annexure-II	
	Processing Fees,	1	
	Empanelment		
	Fees.		
В	Technical documents	Manufacturing License	
		Manufacturing License renewal /validity	
		certificate	
		Non Conviction Certificate issued by the	
		Drugs Controller	
		Good Manufacturing Practices Certificate	
		Import License, if imported.	
		Sale License, in the case of imported drugs	
		Copy of record of import to establish 3 years	
		market standing, if imported.	
		Product Permissions by the Licensing	
		Authority for each and every product quoted	
		Market Standing Certificate issued	
		by the licensing Authority	
		Annexure-VI Check List Of Details Regarding	
~		Products Quoted	
C	Other	Documentary evidence for the constitution of	
	Documents	the company / concern	
		The instruments such as power of attorney	
		resolution of board etc	
		Copies of balance sheet & profit loss	
		account for three years	
		Sales Tax clearance certificate	
		Excise Registration Certificate	
		Copy of PAN	
		Annual Turnover Statement	
		Annexure-VII Declaration and Undertaking	
		Annexure-XI Undertaking For Empanelment	

Annexure – VI Ref. Clause No. 5 (u)

Check list of details regarding products quoted

	Produ	ict permissio	on as per cor	ndition no. 5 ((c) and Marke	t Stand	ling as	per con	dition 5 (g)
S. No.	Quoted Item /Code no.	Product permission enclosed on page		Product permission of formulation	Specification as per Code no. Yes/ No	produ		MSC fg & last 3	Attested	Remark
		no.	Approval	Generic /		Page		Date		
				Branded		No.	No	of Issue		
1										
2										
3										
4										
5										

Annexure – VII

Ref. Clause No. 5 (o),(q),(r),(t),(v),(w)

Declaration & Undertaking

(For F.02(126)/RMSC/PR	COCURMENT/DRUC	G/NIB-05/2014/485 Dated 12.	05.2014)
(On Non-Judicial St	amp Paper of Rs 5	500/- Attested by Notary I	Public)
I NameS/o.	Age	eProp./Partner/Direction	ctor/Power
of attorney holder of firm	n M/s	situated at (Comple	ete address
of Mfg. unit)	bearing drug li	cense on Form 25 & 28 o	or form 10
bearing Number	&	respectively,	issued on
datedvali	d/Renewed up to.	do here	by declare
on oath as follows:-			

- 1. That none of the quoted Drug and Medicines manufactured / imported by us since grant of above drug license have been found as of spurious or adulterated quality and no case in this regard is pending in any court.
- 2. That the quoted product is manufactured/imported by us, and none has been declared as "Not of standard quality" during last two years.
- 3. That we have following Commitment of quantity in our plant at above address:-[Ref. Clause No. 24(i)]

S.	Quoted	Monthly	Annual	Monthly	Annual	Estimated Bid
No.	item Code	Capacity in	Production	supply	Supply	Quantity as
	No. &	all shifts in	Capacity	Commitmen	Commitment	per Annexure
	Name of	nos.		t to RMSC	to RMSC in	VIII
	Drugs			in nos.	nos.	
1.						
2.						

4. That concern/company/firm does not stand blacklisted/banned/debarred on any ground by Bid Inviting Authority or Govt. of Rajasthan or its departments on the date of bid submission. The concern/company/firm does not stand blacklisted/banned/debarred on the ground of conviction by court of law or the products being found spurious or adulterated by any other State /Central Government or it's any agencies (central Drugs procurement agencies). But my firm is blacklisted/banned/debarred different ground by on a procurement agency, the details of which are given below------(Write 'NIL' if no such matter exists)

- 5. That our Firm/Company and its Proprietor/Partner/Directors/ Power of attorney holders have not been convicted for contravention of any provisions of Drugs & Cosmetic Act 1940 and rules made there under since grant of license.
- 6. That we have been granted product permission by the State Licensing Authority for manufacture of quoted products as per the details given below:-

S. No.	Code No.	Name of the Product	_	Date of product permission obtained from the Licensing Authority	Endorsement is in Generic or Trade	0
1.						
2.						

- 7. That we have over three years' experience in the manufacture of the quoted product, or the quoted imported product has over 3 years market standing.
- 9. That we hereby confirm that we have deposited all the VAT/Sale Tax as on......With the department No VAT/CST is due on M/s.....as on.....
- 10. That I will supply the Drug and Medicines per the designs given in Bid clause no 14 and as per the instructions given in this regard.
- 11. That I/We have carefully read all the conditions of Bid in Ref. no. F.02(126)/RMSC/PROCURMENT/DRUG/NIB-05/2014/485 Dated 12.05.2014 for Annual Rate Contract cum Supply, of Drugs and Medicines for Rajasthan Medical Services Corporation and accept all conditions of Bid, including amendments if any.

- 12. I/We agree that the Bid Inviting Authority forfeiting the Bid security Deposit and or Performance Security and blacklisting /Debarring/Banning me/ us for a period of 5 years or as deemed fit if, any information furnished by us proved to be false/fabricated at the time of inspection and not complying the conditions as per Schedule M of the said Act or at any time during the Bid process.
- 13. I/ we hereby declare under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012. that:
 - a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
 - b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the State Government or any local authority as specified in the Bidding Document;
 - c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;
 - d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
 - e. I/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition.
- 14. The quoted rates of any items is not more than the price fixed by the govt. under the current drugs (Price control) order.

15. Our	complete	address	for
communicat	ion		
		Pin	
E-mail addre	ess:		
Phone No. /	Mobile No		

16. Bank detail for e banking :-	
Name of account holder	
Full name of Bank with Branch	
Address of Bank	
A/c no. with full digits	
IFSC code	
17. Authorized/nominating person	DI . 1 6
Name:	Photograph of Authorized/ nominating person
Designation:-	
Organization:-	
Complete address for communication:-	Signature of
Pin	Authorized / nominating person
E-mail address:-	
Phone No./Mobile No.	4
(Name of Deponent & Signation	nature)
<u>Verification</u>	
I(Designation)	
Affirm on oath that the contents/information from para 1 to 17 as me	ntioned
above, are true & correct to the best of my knowledge and nothing is h	idden. I
also declare on oath, that if any information furnished by me as above i	s found
wrong, false, forged or fabricated; the Corporation will be at liberty to	cancel
the Bid for which I shall be solely responsible and the firm r	nay be
Debarred/Banned/ blacklisted / prosecuted for the same.	
(Name of Deponent & Sign	nature)
Witness:- (Name, Address & Signature)	
1	
2	
*The GMP certificate must not be older than one year from the last date	e of Bid

submission in case validity is not mentioned in the certificate.

List of Drugs with Specifications

S. No	Code No.	Name of item with specification	Packing Unit	Estimated Bid Qty.(No. of tabs, Caps, ampoules, bottles, tubes, etc.)	Minimum labelled Shelf Life (In Months)
1	2	3	4	5	6
1.	4	Bupivacaine Injection IP 0.5%	20 ml Vial	210	24
2.	6	Halothane BP 250 ml	250 ml in Amber coloured bottle	2412	36
3.	9	Lignocaine Ointment 5%	10 gm tube in unit carton	50000	24
4.	14	Propofol Injection IP 10 mg/ ml	20 ml Vial / Ampoule	32462	36
5.	16	Aspirin Tablets IP 300mg	10x10 Tab strip	4175629	24
6.	19	Diclofenac Sodium Injection IP 25 mg/ ml (IM/IV use)	3 ml Amp (10 Amp)	13625543	36
7.	31	Pethidine Hydrochloride Injection IP 50mg/ml (IM/IV use)	1ml Amp (25 ampoules)	3670	24
8.	51	Naloxone Injection IP 0.4mg/ ml	1ml Amp (10 ampoules)	2769	24
9.	59	Phenytoin Tablets IP 100 mg (Film Coated)	10x10 Tab strip	4564703	36
10.	60	Sodium Valproate Injection 100 mg/ ml	5 ml Vial	80432	36
11.	61	Sodium Valproate Tablets 200 mg (Enteric Coated)	10x10 Tab strip	3364105	36
12.	63	Acyclovir Tablets IP 200 mg	10 x10 Tab Blister	719785	36
13.	80A	Azithromycin Tablets IP 500 mg	10x3x3 Tab strip/blister (Blister/strip of 3 Tablets)	19359532	24
14.	81	Benzathine Benzylpenicillin Inj IP 12 lac units	Vial	30789	36
15.	82	Benzathine Benzylpenicillin Inj IP 6 lac units	Vial	77	24
16.	85	Cefixime Tablets IP 200 mg	10 x 10 Tab strip	49870473	24
17.	94	Ceftriaxone Injection IP 250 mg/ vial	Vial (Packed in mono carton)	1044404	30
18.	99	Chloroquine Phosphate Tab. IP 250mg (≡155 mg of Chloroquine base) (Film Coated)	10 x10 Tab strip/ Blister	47024891	36
19.	102	Ciprofloxacin Tablets IP 250 mg (Film Coated)	10 x10 Tab Blister	28118676	36

21. 122 Metronidazole Tablets IP 200 mg I0 x 10 Tab Blister	20.	103	Ciprofloxacin Tablets IP 500 mg	10 x10 Tab	47887399	36
CFilm Coated CFil	21	100	(Film Coated)	Blister	2046102	26
22. 125	21.	122	_		3846193	36
23. 133 Azathioprine Tablets IP 50 mg 10 x 10 tablets 15950 36 24. 135 Calcium Folinate Tablets BP/Leucovorin Calcium Tablet USP Cal. Folinate eq. to Folinic Acid / Leucovorin 15 mg 25 136 Chlorambucil Tablets IP 5 mg 30 Tablets 2673 24 25. 136 Chlorambucil Tablets IP 5 mg 30 Tablets 2673 24 26. 137 Cisplatin Injection IP 50 mg/50ml 50 ml Vial 22477 24 27. 138 Cyclophosphamide Injection IP 200 10 ml glass vial 6844 24 mg 28 141 Cytarabine Injection IP 100 mg / 5 ml 5 ml glass vial 20040 36 30 147 Flunarizine Tablets 5 mg 10 x10 Tab Blister 31 150 Leucovorin Calcium Injection IP 10 mg /ml 5 ml Vial 12177 24 152 Mercaptopurine Tablets IP 5 mg 25 Tab Bottle 963 24 33 152 Mercaptopurine Tablets IP 50 mg 10 x 10 Tab strip 35 155 Paclitaxel Injection IP 260 mg 43.4 ml Vial 9622 24 36 157 Tamoxifen Tablets IP 10 mg 10 x 10 Tab strip 37 158 Vinistine Injection IP Img/ In 10 ml Vial 98384 24 24 39 Vincristine Injection IP Img/ In 10 ml Vial 98384 24 39 160 Levodopa and Carbidopa Tablets IP 10 mg 10 x 10 Tab strip 37 158 Vinistine Injection IP Img/ In 10 ml Vial 690 24 38 159 Vincristine Injection IP Img/ In 1 ml Vial 38 24 39 Vincristine Injection IP Img/ In 1 ml Vial 38 24 39 Vincristine Injection IP Img/ In 1 ml Vial 38 24 36 161 Levodopa 250mg and Carbidopa Tablets IP 2 mg 10 x 10 Tab strip 78155 36 36 36 36 36 36 36	22	105	,		22006420	2.4
23. 133	22.	125	Offoxacin Tablets IP 200 mg		23906439	24
24, 135 Calcium Folinate Tablets BP/Leucovorin Calcium Tablet USP Cal, Folinate eq. to Folinic Acid /Leucovorin 15 mg 10x10 Tab Strip 59389 36	22	100	A 41 T 11 T 70 T0		15050	26
24. 135	23.	133	Azathioprine Tablets IP 50 mg		15950	36
Calcium Tablet USP Cal. Folinate eq. to Folinic Acid /Leucovorin 15 mg	2.4	105	G 1 : F 1 : F 11 : F D G	-	50200	2.5
Folinic Acid /Leucovorin 15 mg	24.	135		10x10 Tab Strip	59389	36
25. 136			_			
26. 137 Cisplatin Injection IP 50 mg/50ml 50 ml Vial 22477 24 27. 138 Cyclophosphamide Injection IP 200 10 ml glass vial 6844 24 28. 141 Cytarabine Injection IP 100mg/ml 5 ml vial 1808 24 29. 146 Etoposide Injection IP 100 mg / 5 ml 5 ml glass vial 20040 36 30. 147 Flunarizine Tablets 5 mg	25	136		30 Tablets	2673	24
26. 137 Cisplatin Injection IP 50 mg/50ml 50 ml Vial 22477 24 27. 138 Cyclophosphamide Injection IP 200 10 ml glass vial 6844 24 28. 141 Cytarabine Injection IP 100mg/ml 5 ml vial 1808 24 29. 146 Etoposide Injection IP 100 mg / 5 ml 5 ml glass vial 20040 36 30. 147 Flunarizine Tablets 5 mg	23.	130	Chioramoden Tablets in 3 mg		2073	24
27. 138	26	137	Cisplatin Injection IP 50 mg/50ml		22477	24
28.						
28. 141 Cytarabine Injection IP 100 mg / 5 ml vial 1808 24	27.	130		10 iiii giass viai	0044	2 4
29. 146 Etoposide Injection IP 100 mg / 5 ml 5 ml glass vial 20040 36 30. 147 Flunarizine Tablets 5 mg 10 x 10 Tab 111265 36 31. 150 Leucovorin Calcium Injection IP 10 mg /ml 5 ml Vial 12177 24 32. 151 Melphalan Tablets IP 5 mg 25 Tab Bottle 963 24 33. 152 Mercaptopurine Tablets IP 50 mg 10 x 10 Tab 4499 24 34. 154 Methotrexate Tablets IP 2.5 mg 10 x 10 Tab 137225 36 35. 155 Paclitaxel Injection IP 260 mg 43.4 ml vial 9222 24 36. 157 Tamoxifen Tablets IP 10 mg 10 x 10 Tab 98384 24 37. 158 Vinblastine Injection IP 10mg/I0ml 10 ml vial 690 24 38. 159 Vincristine Injection IP 10mg/ I0ml 1 ml vial 381 24 39. 160 Levodopa and Carbidopa Tablets IP 1 ml vial 381 24 40. 161<	28	1/1		5 ml viol	1808	24
30.						
Solution Strip S			1 1			
31. 150 Leucovorin Calcium Injection P/Calcium Folinate Injection IP 10 mg/ml 32. 151 Melphalan Tablets IP 5 mg 25 Tab Bottle 963 24 33. 152 Mercaptopurine Tablets IP 50 mg 10 x 10 Tab 4499 24 34. 154 Methotrexate Tablets IP 2.5 mg 10 x 10 Tab strip 35. 155 Paclitaxel Injection IP 260 mg 43.4 ml vial 9222 24 36. 157 Tamoxifen Tablets IP 10 mg 10 x 10 Tab 98384 24 37. 158 Vinblastine Injection IP 10mg/ 10ml 10 ml vial 690 24 38. 159 Vincristine Injection IP 1mg/ ml 1 ml vial 381 24 39. 160 Levodopa and Carbidopa Tablets IP 10 x10 Tab strip 78155 36 36 37. 160 Levodopa 250mg and Carbidopa 10 mg 10 x10 Tab strip 78155 36 36 37. 38. 167 Deferajorne Capsules 250 mg 30 Tab 468862 24 34. 167 Deferiprone Capsules 500 mg 50 Caps 30300 36 36 36 36 37. 38 38 38 39 39 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 36 30 30	30.	14/	Fiunarizine Tablets 5 mg		111203	30
IP/Calcium Folinate Injection IP 10 mg/ml 25 Tab Bottle 963 24 33. 152 Mercaptopurine Tablets IP 5 mg 10 x 10 Tab 4499 24 strip 34. 154 Methotrexate Tablets IP 2.5 mg 10 x 10 Tab 137225 36 35. 155 Paclitaxel Injection IP 260 mg 43.4 ml vial 9222 24 36. 157 Tamoxifen Tablets IP 10 mg 10 x 10 Tab 8384 24 37. 158 Vinblastine Injection IP 10mg/ 10ml 10 ml vial 690 24 38. 159 Vincristine Injection IP 1mg/ml 1 ml vial 381 24 39. 160 Levodopa and Carbidopa Tablets IP 10 x 10 Tab strip 78155 36 161 Levodopa 250mg and Carbidopa 10 mg 40. 161 Levodopa 250mg and Carbidopa 25 10 x 10 Tab strip 268015 24 mg Tab IP 41. 163 Acenocoumarol Tablets IP 2 mg 10x10 Tab strip 174801 24 (Nicoumalone Tab IP) 42. 165 Deferasirox Tablets 100 mg 30 Tab 468862 24 43. 167 Deferiprone Capsules 250 mg 50 Caps 30300 36 44. 168 Deferiprone Capsules 500 mg 50 Caps 75900 24 45. 173 Ethamsylate Injection 250 mg/2ml 2 ml Amp 457130 24 (IM/IV) 46. 183 Amiodarone Hydrochloride Injection 3 ml Amp 16502 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab 8440603 24 48. 187 Atorvastatin Tablets IP 10 mg 10x10 Tab 8440603 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49. 49.	21	150	I avecyonin Coloium Injection		12177	24
Section	31.	130		Silli Viai	12177	24
32. 151 Melphalan Tablets IP 5 mg 25 Tab Bottle 963 24 33. 152 Mercaptopurine Tablets IP 50 mg 10 x 10 Tab 4499 24 34. 154 Methotrexate Tablets IP 2.5 mg 10 x 10 Tab 137225 36 35. 155 Paclitaxel Injection IP 260 mg 43.4 ml vial 9222 24 36. 157 Tamoxifen Tablets IP 10 mg 10 x 10 Tab 98384 24 37. 158 Vinblastine Injection IP 10mg/ 10ml 10 ml vial 690 24 38. 159 Vincristine Injection IP 1mg/ ml 1 ml vial 381 24 39. 160 Levodopa and Carbidopa Tablets IP 10 x10 Tab strip 78155 36 Levodopa 100mg + Carbidopa 10 mg 10 x10 Tab strip 268015 24 40. 161 Levodopa 250mg and Carbidopa 25 10 x10 Tab strip 268015 24 mg Tab IP 10 x10 Tab strip 174801 24 41. 163 Acenocoumarol Tablets IP 2 mg 10x10 Tab strip 174801 24 (Nicoumalone Tab IP) 20 Caps 30300 36 44. 168 Deferiprone Capsules 250 mg 50 Caps 30300 36 44. 168 Deferiprone Capsules 500 mg 50 Caps 75900 24 45. 173 Ethamsylate Injection 250 mg/ 2ml (10 ampoules) (10 ampoules) 46. 183 Amiodarone Hydrochloride Injection 3 ml Amp 16502 24 46. 183 Amiodarone Hydrochloride Injection 3 ml Amp 16502 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab 8440603 24 48. 187 Atorvastatin Tablets IP 10 mg 10x10 Tab 8440603 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 40. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 20. 2			· · · · · · · · · · · · · · · · · · ·			
33. 152 Mercaptopurine Tablets IP 50 mg 10 x 10 Tab strip 34. 154 Methotrexate Tablets IP 2.5 mg 10 x 10 Tab strip 36. 35. 155 Paclitaxel Injection IP 260 mg 43.4 ml vial 9222 24 36. 157 Tamoxifen Tablets IP 10 mg 10 x 10 Tab strip 98384 24 strip 37. 158 Vinblastine Injection IP 10mg/10ml 10 ml vial 690 24 38. 159 Vincristine Injection IP 1mg/ml 1 ml vial 381 24 39. 160 Levodopa and Carbidopa Tablets IP 10 x10 Tab strip 78155 36 Levodopa 100mg + Carbidopa 10 mg 10 x10 Tab strip 268015 24 mg Tab IP 41. 163 Acenocoumarol Tablets IP 2 mg 10x10 Tab strip 174801 24 (Nicoumalone Tab IP) 42. 165 Deferasirox Tablets 100 mg 30 Tab 468862 24 43. 167 Deferiprone Capsules 250 mg 50 Caps 30300 36 44. 168 Deferiprone Capsules 500 mg 50 Caps 30300 36 44. 168 Deferiprone Capsules 500 mg 50 Caps 75900 24 45. 173 Ethamsylate Injection 250 mg/2ml 2 ml Amp 457130 24 (IM/IV) (10 ampoules) 46. 183 Amiodarone Hydrochloride Injection 3 ml Amp 16502 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab 8440603 24 48. 187 Atorvastatin Tablets IP 10 mg 10x10 Tab 8440603 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 49. 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40.	22	151	<u> </u>	25 Tab Dattle	062	24
34. 154 Methotrexate Tablets IP 2.5 mg 10 x 10 Tab 137225 36						
34. 154 Methotrexate Tablets IP 2.5 mg 10 x 10 Tab strip 36	33.	152	Mercaptopurine Tablets IP 50 mg		4499	24
Strip	24	151	Mathatravata Tableta ID 25 mg	-	127225	26
35. 155 Paclitaxel Injection IP 260 mg 43.4 ml vial 9222 24 36. 157 Tamoxifen Tablets IP 10 mg 10 x 10 Tab 98384 24 37. 158 Vinblastine Injection IP 10mg/ 10ml 10 ml vial 690 24 38. 159 Vincristine Injection IP 1mg/ ml 1 ml vial 381 24 39. 160 Levodopa and Carbidopa Tablets IP 10 x10 Tab strip 78155 36 40. 161 Levodopa 250mg and Carbidopa 25 10 x10 Tab strip 268015 24 41. 163 Acenocoumarol Tablets IP 2 mg 10x10 Tab strip 174801 24 42. 165 Deferasirox Tablets 100 mg 30 Tab 468862 24 43. 167 Deferiprone Capsules 250 mg 50 Caps 30300 36 44. 168 Deferiprone Capsules 500 mg 2 ml Amp 457130 24 45. 173 Ethamsylate Injection 250 mg/ 2ml 2 ml Amp 16502 24 46. 183	34.	154	Methotrexate Tablets IP 2.5 mg	_	13/223	30
36. 157 Tamoxifen Tablets IP 10 mg 10 x 10 Tab 98384 24 37. 158	25	155	Declitored Injection ID 260 mg		0222	24
37. 158 Vinblastine Injection IP 10mg/ 10ml 10 ml vial 690 24			i i			
37. 158 Vinblastine Injection IP 10mg/ 10ml 10 ml vial 690 24 38. 159 Vincristine Injection IP 1mg/ ml 1 ml vial 381 24 39. 160 Levodopa and Carbidopa Tablets IP Levodopa 100mg + Carbidopa 10 mg 10 x10 Tab strip 78155 36 40. 161 Levodopa 250mg and Carbidopa 25 mg Tab IP 10 x10 Tab strip 268015 24 41. 163 Acenocoumarol Tablets IP 2 mg (Nicoumalone Tab IP) 10x10 Tab strip 174801 24 42. 165 Deferasirox Tablets 100 mg 30 Tab 468862 24 43. 167 Deferiprone Capsules 250 mg 50 Caps 30300 36 44. 168 Deferiprone Capsules 500 mg 50 Caps 75900 24 45. 173 Ethamsylate Injection 250 mg/2ml (10 ampoules) 2 ml Amp (1502 24 46. 183 Amiodarone Hydrochloride Injection 3 ml Amp (10 ampoules) 16502 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab Blister 8440603 24	36.	157	Tamoxifen Tablets IP 10 mg		98384	24
38. 159 Vincristine Injection IP Img/ml 1 ml vial 381 24 39. 160 Levodopa and Carbidopa Tablets IP Levodopa 100mg + Carbidopa 10 mg 10 x10 Tab strip 78155 36 40. 161 Levodopa 250mg and Carbidopa 25 mg Tab IP 10 x10 Tab strip 268015 24 41. 163 Acenocoumarol Tablets IP 2 mg (Nicoumalone Tab IP) 10x10 Tab strip 174801 24 42. 165 Deferasirox Tablets 100 mg 30 Tab 468862 24 43. 167 Deferiprone Capsules 250 mg 50 Caps 30300 36 44. 168 Deferiprone Capsules 500 mg 50 Caps 75900 24 45. 173 Ethamsylate Injection 250 mg/ 2ml 2 ml Amp 457130 24 46. 183 Amiodarone Hydrochloride Injection 3 ml Amp 16502 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab 22389471 36 48. 187 Atorvastatin Tablets IP 10 mg 10x10 Tab 8440603 24 <td>37.</td> <td>158</td> <td>Vinblastine Injection IP 10mg/ 10ml</td> <td>•</td> <td>690</td> <td>24</td>	37.	158	Vinblastine Injection IP 10mg/ 10ml	•	690	24
39. 160 Levodopa and Carbidopa Tablets IP Levodopa 100mg + Carbidopa 10 mg 10 x10 Tab strip 78155 36 40. 161 Levodopa 250mg and Carbidopa 25 mg Tab IP 10 x10 Tab strip 268015 24 41. 163 Acenocoumarol Tablets IP 2 mg (Nicoumalone Tab IP) 10x10 Tab strip 174801 24 42. 165 Deferasirox Tablets 100 mg 30 Tab 468862 24 43. 167 Deferiprone Capsules 250 mg 50 Caps 30300 36 44. 168 Deferiprone Capsules 500 mg 50 Caps 75900 24 45. 173 Ethamsylate Injection 250 mg/2ml (10 ampoules) 2 ml Amp (10 ampoules) 457130 24 46. 183 Amiodarone Hydrochloride Injection (10 ampoules) 3 ml Amp (10 ampoules) 16502 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab (10x10 Tab (10x			y c			
Levodopa 100mg + Carbidopa 10 mg 40. 161 Levodopa 250mg and Carbidopa 25 10 x 10 Tab strip 268015 24 24 268015 24 24 25 25 25 25 25 2			j Ç			
40. 161 Levodopa 250mg and Carbidopa 25 mg Tab IP 10 x10 Tab strip 268015 24 41. 163 Acenocoumarol Tablets IP 2 mg (Nicoumalone Tab IP) 10x10 Tab strip 174801 24 42. 165 Deferasirox Tablets 100 mg 30 Tab 468862 24 43. 167 Deferiprone Capsules 250 mg 50 Caps 30300 36 44. 168 Deferiprone Capsules 500 mg 50 Caps 75900 24 45. 173 Ethamsylate Injection 250 mg/2ml (10 ampoules) 2 ml Amp (10 ampoules) 457130 24 46. 183 Amiodarone Hydrochloride Injection 50 mg/ml 3 ml Amp (10 ampoules) 16502 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab Blister 22389471 36 48. 187 Atorvastatin Tablets IP 10 mg 10x10 Tab Blister 8440603 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24			1 1	The state of the s		
Mag Tab IP	40.	161		10 x 10 Tab strip	268015	24
41. 163 Acenocoumarol Tablets IP 2 mg (Nicoumalone Tab IP) 10x10 Tab strip 174801 24 42. 165 Deferasirox Tablets 100 mg 30 Tab 468862 24 43. 167 Deferiprone Capsules 250 mg 50 Caps 30300 36 44. 168 Deferiprone Capsules 500 mg 50 Caps 75900 24 45. 173 Ethamsylate Injection 250 mg/ 2ml (10 ampoules) 2ml Amp (10 ampoules) 457130 24 46. 183 Amiodarone Hydrochloride Injection 50 mg/ml 3 ml Amp (10 ampoules) 16502 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab Blister 22389471 36 48. 187 Atorvastatin Tablets IP 10 mg 10x10 Tab Blister 8440603 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24						
(Nicoumalone Tab IP)	41.	163		10x10 Tab strip	174801	24
42. 165 Deferasirox Tablets 100 mg 30 Tab 468862 24 43. 167 Deferiprone Capsules 250 mg 50 Caps 30300 36 44. 168 Deferiprone Capsules 500 mg 50 Caps 75900 24 45. 173 Ethamsylate Injection 250 mg/ 2ml (I0 ampoules) 2 ml Amp (10 ampoules) 457130 24 46. 183 Amiodarone Hydrochloride Injection 50 mg/ml 3 ml Amp (10 ampoules) 16502 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab Blister 22389471 36 48. 187 Atorvastatin Tablets IP 10 mg 10x10 Tab Blister 8440603 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24			ε	r		
43. 167 Deferiprone Capsules 250 mg 50 Caps 30300 36 44. 168 Deferiprone Capsules 500 mg 50 Caps 75900 24 45. 173 Ethamsylate Injection 250 mg/ 2ml (IM/IV) 2 ml Amp (10 ampoules) 457130 24 46. 183 Amiodarone Hydrochloride Injection 50 mg/ml 3 ml Amp (10 ampoules) 16502 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab Blister 22389471 36 Blister 48. 187 Atorvastatin Tablets IP 10 mg Blister 10x10 Tab Blister 8440603 24 Blister 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24	42.	165	,	30 Tab	468862	24
44. 168 Deferiprone Capsules 500 mg 50 Caps 75900 24 45. 173 Ethamsylate Injection 250 mg/ 2ml (IM/IV) 2 ml Amp (10 ampoules) 457130 24 46. 183 Amiodarone Hydrochloride Injection 50 mg/ml 3 ml Amp (10 ampoules) 16502 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab Blister 22389471 36 48. 187 Atorvastatin Tablets IP 10 mg 10x10 Tab Blister 8440603 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24			8			
45. 173 Ethamsylate Injection 250 mg/ 2ml (IM/IV) 2 ml Amp (10 ampoules) 457130 24 46. 183 Amiodarone Hydrochloride Injection 50 mg/ml 3 ml Amp (10 ampoules) 16502 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab Blister 22389471 36 48. 187 Atorvastatin Tablets IP 10 mg 10x10 Tab Blister 8440603 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24			1 1			
(IM/IV) (10 ampoules) 46. 183 Amiodarone Hydrochloride Injection 50 mg/ml 3 ml Amp (10 ampoules) 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab Blister 22389471 36 48. 187 Atorvastatin Tablets IP 10 mg 10x10 Tab Blister 8440603 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24						
46. 183 Amiodarone Hydrochloride Injection 50 mg/ml 3 ml Amp (10 ampoules) 16502 24 47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab Blister 22389471 36 48. 187 Atorvastatin Tablets IP 10 mg 10x10 Tab Blister 8440603 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24		-	•	-	-	
50 mg/ml	46.	183	` '	` • ′	16502	24
47. 185 Amlodipine Tablets IP 5 mg 10x10 Tab 22389471 36 48. 187 Atorvastatin Tablets IP 10 mg 10x10 Tab 8440603 24 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24		-	_	-		
Blister	47.	185		<u> </u>	22389471	36
48. 187 Atorvastatin Tablets IP 10 mg 10x10 Tab 8440603 24 Blister 49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24			1		· -	
Blister 24750 24	48.	187	Atorvastatin Tablets IP 10 mg		8440603	24
49. 189 Digoxin Injection IP 0.25 mg/ml 2 ml Amp 24750 24		- *			/-	
	49.	189	Digoxin Injection IP 0.25 mg/ml		24750	24
			<i>y</i>	-		

50.	197	Isosorbide dinitrate Tablets IP 5 mg	10x10 Tab Blister	1754803	36
51.	211	Verapamil Tablets IP 40 mg (Film Coated)	10x10 Tab Strip	99811	30
52.	212	Verapamil Injection IP 2.5 mg/ml	2 ml Amp (25 Ampoules)	3991	24
53.	213	Acyclovir Cream 5%	5 gm tube in unit carton	86142	36
54.	221	Povidone Iodine ointment 5%	15 gm Tube in unit carton	6440444	24
55.	225	Anti A Blood Grouping Serum IP (Anti A Monoclonal Serum)	10 ml Vial	13066	12
56.	226	Anti B Blood Grouping Serum IP (Anti B Monoclonal Serum)	10 ml Vial	12742	12
57.	227	Anti DRh Blood Grouping Serum	10 ml Vial	14947	12
58.	229	Barium Sulphate Suspension IP 100%	500 ml	7088	24
59.	245	Formaldehyde Solution (34.5% - 38%)	450 ml bottle	13014	24
60.	254	Frusemide Tablets IP 40 mg.	10 x 10 Tabs Strips	4064704	36
61.	258	Spironolactone Tablets IP 25 mg	10x10 Tab Blister	1453135	36
62.	265	Dicyclomine Hydrochloride Oral Solution IP 10mg /5ml	30 ml Bottle (With Measuring Cap)	419964	24
63.	266	Domperidone Suspension IP 5 mg/5ml	30 ml Bottle (With Measuring Cap)	1514206	24
64.	272	Omeprazole Capsules IP 20 mg	10x10 Cap Strip	85107827	24
65.	280	Carbimazole Tabs IP 5 mg (Film Coated)	10x10 Tab Blister	93489	24
66.	283	Clomiphene Tablets IP 50 mg	10 x10 Tab strip	55275	36
67.	285	Dinoprostone Cream/Gel 0.5 mg Dinoprostone in syringe	Syringe	68689	24
68.	286	Ethinyloestradiol Tabs IP 50 mcg	10x10 Tab Strip	66280	36
69.	293	Hydroxyprogesterone Injection IP 250mg/ ml	1 ml Amp (25 ampoules)	169108	24
70.	298	Progesterone Injection 200 mg/ 2ml	2 ml Amp (10 Ampoules)	130492	24
71.	304	Human Anti D Immunoglobulin 150 mcg	PFS/ Vial	3670	24
72.	305	Human Rabies Immunoglobulin Injection 150 IU/ ml	2 ml vial/Ampoule/P FS	26755	24
73.	307	Rabies Vaccine Human (Cell Culture) IP (Intramuscular) 2.5 IU/ dose	Single dose vial with diluent and syringe with needle	969274	24
74.	316	Neostigmine Tablets IP 15 mg	10x10 Tab strip	14410	36

		_			
75.	317	Succinylcholine Injection IP 50 mg/ml (IV use)	10 ml Vial	18092	24
76.	319	Atropine Eye Ointment IP 1%	3 gm Tube in unit carton	23222	24
77.	320	Atropine Sulphate Ophthalmic	5ml vial with	31546	24
' '	320	Solution USP 1%	sterilized	31310	21
		Solution CST 170	dropper, or		
			squeeze vial		
			Squoo20 +IMI		
78.	330	Tobramycin and Dexamethasone	5ml vial with	1041325	24
		Ophthalmic Suspension USP	sterilized		
		0.3%+0.1%	dropper packed		
			in separate		
			polythene pack		
79.	333	Isoxsuprine Injection IP 5 mg/ml	2 ml Amp	63115	24
			(10 Ampoules)		
80.	339	Alprazolam Tablets IP 0.25 mg	10x10 Tab	9047742	36
			Blister		
81.	340	Alprazolam Tablets IP 0.5mg	10x10 Tab	11176692	36
			Blister		
82.	342	Chlordiazepoxide Tablets IP 10mg	10 x10 Tab	849827	24
			Strip		
83.	344	Chlorpromazine Tablets IP 25 mg	10 x10 Tab	152398	36
		(Sugar- Coated)	Strip		
84.	346	Chlorpromazine Inj. IP 25mg/ml	2 ml Amp	83	36
			(25 ampoules)		
85.	347	Clomipramine Capsules IP 25 mg	10x10 Cap strip	220925	24
86.	348	Clonazepam Tablets IP 1 mg	10x10 Tab Strip	3418619	36
			/ blister		
87.	350	Diazepam Tablets IP 5 mg	10x10 Tab strip/	1937279	24
			blister		
88.	354	Haloperidol Tablets IP 1.5 mg	10x10 Tab strip	116358	24
89.	356	Imipramine Tablets IP 25 mg	10x10 Tab	697381	36
		(Coated Tablets)	Blister		
90.	358	Lithium Carbonate Tablets IP 300 mg	10 x10 Tab	357022	24
			Strip		
91.	359	Lorazepam Injection 2 mg/ml	2 ml Amp	42420	24
			(25 ampoules)	0.44.45.55	-
92.	360	Olanzapine Tablets IP 5 mg	10x10 Tab strip	3614200	36
93.	363	Sertraline Tablets 50 mg	10x10 Tab	1802922	36
0.4	261	m'd mil m	Strip/ Blister	246070	2.4
94.	364	Trifluperazine Tablets IP 5 mg	10 x 10 Tab	246979	24
0.5	27.	(Coated)	Strip /blister	22/10/10	2.4
95.	376	Theophylline Tablets 400 mg	10x10 Tab	2361810	24
		Sustained release/controlled release	Blister		
		(Theophylline prolonged Release			
06	200	Tablets IP)	10 I 4 D1	1.4700	2.4
96.	399	Concentrated Haemodialysis Fluid	10 Ltrs Plastic	14700	24
		B.P Acetate concentrate in 10	Can		
		Litre Cans. Each 1000ml			
		After 1:34 dilutions should provide			
		Sodium chloride 135 to 140 meq/litre			

Sodium Acetate 35-38 meq./ILitre Potassium Chloride 1.5-2meq./Litre Magnesium Chloride 1-1.5meq./Litre Calcium Chloride 0-3 meq./Litre (depending on local condition) Water Purified to 1000ml. Polygeline 3.5% Solution with 97. 405 500 ml Plastic 5189 24 electrolytes for I.V. Infusion Bottle 406 Factor – IX Concentrate (Purified) 98. Vial with 1366 24 600 I.U. (Human Coagulation Factor solvent IX) 99. 413 Nitrofurantoin Tablets IP 100mg 10 x 10 Tab 188474 24 Blister Hyoscine Butyl Bromide Tablets IP 414 10x10 Tab 747274 100. 36 10mg Blister (Coated Tablets) Cloxacillin sodium Injection IP 500 101. 417 24 Vial 41720 Hyaluronidase Injection IP Each vial 102. 423 Vial 9967 36 contains Hyaluronidase IP 1500 I.U. Fluconazole Eye Drops 0.3% 103. 425 5 ml vial with 25215 24 sterilized dropper, or, squeeze vial. 10 x 10 Tab 104. 433 Ranitidine Tablets IP 300mg (Film 7018110 24 Coated) strip 105. 442 Saline Nasal Solution (Drops) 10 ml bottle 647336 36 (Sodium chloride 0.65%) with dropper / Squeeze bottle 10 x 14 Tablets 106. 444 Aspirin Delayed Release Tablets / 8786621 24 Aspirin Gastroresistant Tablets. Each Strip enteric coated tablet contains Acetyl Salicylic Acid 75 mg Chlorhexidine Gluconate Solution 5% 107. 447 250 ml bottle 45866 24 Amlodipine and Enalapril Maleate 108. 457 10 x 10 Tab 803385 24 Tablet (Amlodipine Besilate Strip equivalent to Amlodipine 5mg. Enalapril maleate 5mg) 463 Enalapril Maleate Tablets IP 10 mg 109. 10 x 10 Tab 786456 36 strip Lisinopril Tablets IP 10 mg 10 x 10 Tab 110. 465 182639 24 strip/ blister 111. 466 Lisinopril Tablets IP 2.5 mg 10 x 10 Tab 51810 24 strip/ blister 10 x 10 Tab 112. 469 Prednisolone Tablets IP 10 mg 1626613 24 strip/Blister 113. 471 Torsemide Injection 10 mg/ml 2 ml Amp 39501 24 (25 Ampoules) Zinc Sulphate Dispersible Tablets IP 10x10 Tab 114. 472 4195521 24 Elemental Zinc 10 mg Strip/ Blister

115.	474	Carbamazepine Oral Suspension USP	100 ml Bottle	16279	24
		100 mg/5ml	with measuring		
			Cap		
116.	480	Diphtheria Antitoxin 10000 IU	Vial	100	24
117.	484	Timolol Eye Drops IP 0.5% w/v	5 ml vial with	9945	24
			sterilized		
			dropper, or		
			squeeze vial		
118.	485	Homatropine Eye Drops IP 2 %	5 ml Vial with	3021	36
			Sterilized		
			dropper, or		
			squeeze Vial		
119.	486	Travoprost Eye Drops IP 0.004%	3 ml Vial with	2483	24
			sterilized		
			dropper, or		
			squeeze vial		
120.	487	Brimonidine Tartrate and Timolol	5ml Vial with	18559	36
		Maleate Eye Drops 0.15% + 0.5%	sterilized		
			dropper, or,		
			squeeze vial		
121.	491	Sevoflurane	250 ml Bottle	829	24
122.	492	Aceclofenac and Paracetamol Tablets	10x10 Tablet	28305250	24
		Aceclofenac 100 mg and Paracetamol	Blister		
100	10.0	325 mg	• • • • • • • • • • • • • • • • • • • •	0.72.7.1.1	
123.	493	Diclofenac Gel: Diclofenac	20 gm Tube in	8525541	24
		Diethylamine 1.16%, Methyl	unit carton		
		salicylate 10%, Linseed oil 3% and			
124	406	Menthol 5%	10x10 Tablet	020150	36
124. 125.	496 497	Mefenamic Acid Tablets BP 500 mg Anticold syrup: Each 5 ml contains	30 ml Bottle	929159 9632146	24
123.	471	Phenylephrine Hydrochloride 2.5 mg,	with measuring	9032140	24
		Chlorpheniramine maleate 1 mg, and	cap		
		Paracetamol 125 mg	Сар		
126.	499	Cetirizine syrup IP 5 mg/ 5ml	30 ml Bottle	999525	24
120.	122	Contizine syrup it 3 mg/ 3mi	with measuring	777525	21
			cap		
127.	500	Acetylcystine Solution USP (Injection	2 ml Ampoule	1054	24
) 200 mg/ ml	(5 ampoules)		
128.	502	Acyclovir Intravenous Infusion IP 250	Vial	5011	24
		mg			
129.	503	Acyclovir Intravenous Infusion IP 500	Vial	2022	24
		mg			
130.	504	Amikacin Injection IP 250 mg	Vial	1503160	24
131.	505	Amoxicillin and Potassium Clavulante	Vial (10 ml)	136189	18
		Injection IP 600 mg	. ,		
132.	506	Amoxicillin and Potassium Clavulante	Vial (20 ml)	193911	18
		Injection IP 1.2 g			
133.	507	Amoxicillin and Potassium Clavulante	30 ml Bottle	1148810	18
		Oral Suspension IP 200 mg + 28.5 mg	with measuring		
		per 5 ml	cap		
134. 135.	509 510		cap Vial Vial	10637 6635	24 24

Cefixime Oral Suspension IP 25 mg/ 136. 511 10 ml Bottle (with 216802 24 a separate ml (Paediatric Drops) dropper, which should be able to screw & cap the bottle) in a unit carton 137. 512 Cefuroxime Axetil Tablets IP 250 mg 10x10 Tablet 749815 24 Strip 138. 513 Clindamycin Capsules IP 150 mg 10x10 Capsule 160009 36 strip/ blister 10x10 Capsule 139. 514 Clindamycin Capsules IP 300 mg 224384 36 strip/ blister 140. 515 Levofloxacin Tablets IP 250 mg 10x10 Tablet 436297 36 Blister 10x10 Tablet 141. 516 Linezolid Tablets IP 600 mg 54747 24 19804 142. 518 Mefloquine Tablets IP 250 mg 10x6 Tablet 36 Blister 143. 519 Metronidazole & Norfloxacin 30 ml Bottle 450942 24 with measuring suspension 100 + 100 mg per 5 mlcap 521 Ofloxacin Infusion IP 200mg/ 100 ml 144. 100 ml Bottle 213224 36 (in NaCl Inj) Pyrimethamine and Sulphadoxine 145. 522 2 Tablet Strip/ 59650 24 Tablets IP (Pyrimethamine 37.5 mg Blister and Sulphadoxine 750 mg) (50 x 2 Tab) Vancomycin for Intravenous Infusion 146. 523 Vial 26444 24 IP 500 mg Vancomycin for Intravenous Infusion 147. 524 Vial 2895 24 Alpha Interferon Injection (Interferon 148. 525 Vial 650 24 Alpha-2 concentrated Solution IP) 3 million unit Carboplatin Injection 150 mg 149. 526 15 ml Vial 638 24 150. 527 Carboplatin Injection 450 mg 45 ml Vial 4797 24 Cisplatin Injection IP 10 mg/ 10 ml 10 ml Vial 151. 528 791 24 Dacarbazine Injection 500 mg USP/ 152. 529 Vial 80 24 153. 530 Filgrastim Injection (Granulocyte PFS/ Vial 528 24 Colony Stimulation Factor) 300 mcg [SC/IV use] Gemcitabine for Injection 200 mg 531 Vial 7407 24 154. 155. 532 Gemcitabine for Injection 1 gm Vial 3080 24 Ifosfamide Injection USP/ BP 1 gm 24 156. 533 Vial 1309 157. 534 Imatinib Tablets 400 mg 10x10 Tablet 1353 24 Methotrexate Tablets IP 10 mg 158. 536 10x10 Tablet 110350 24 Strip Vial 159. 537 Mitomycine Injection 10 mg 341 24 $1\overline{60}$. Oxaliplatin Injection USP 50 mg 538 25 ml Vial 2574 24 Bromocriptine Tablets IP 1.25 mg 161. 539 10x10 Tablet 17500 24 Strip

		-			
162.	540	Bromocriptine Tablets IP 2.5 mg	10x10 Tablet Strip	17000	24
163.	541	Betahistine Tablets IP 8 mg	10x10 Tablet	36430	36
164.	542	Betahistine Tablets IP 16 mg	10x10 Tablet	86783	36
165.	544	Cinnarizine Tablets IP 75 mg	10x10 Tablet	1200570	24
130.		- Canada Lacrots La ye ang	Blister	1200070	
166.	545	Tranexamic Acid Tablets 500 mg	10x6 Tablet	1516165	36
			Blister		
167.	546	Warfarin Sodium Tablets IP 5 mg	10x10 Tablet	41985	24
168.	547	Adenosine Injection 6 mg/ 2 ml	2 ml	782	24
			Vial/Ampoule		
169.	548	Atorvastatin Tablets IP 40 mg	10x10 Tablet	1840260	24
170.	549	Clopidogrel and Aspirin Tablets	10x10 Tablet	4351600	24
		Clopidogrel 75 mg and Aspirin 75 mg	Strip		
171.	550	Fenofibrate Capsules IP 200 mg	10x10 Capsule	403165	24
172.	551	Isoprenaline Injection IP 2mg / ml	1 ml Ampoule	3290	24
			(5 Ampoules)		
173.	554	Noradrenaline Injection IP 2 mg/ ml	2 ml Amp/ Vial	127200	18
174.	555	Prazosin Tablets (Extended Release)	10x14 Tablet	163250	24
155		2.5 mg	strip /blister	0.50	
175.	557	Urokinase Injection 5 Lac Unit	Vial	868	24
176	550	(Lyophilized)	1.5	150500	2.4
176.	558	Betamethasone Dipropionate Cream IP 0.05%	15 gm	150500	24
177.	559	Betamethasone Lotion IP 0.05%	50 ml	24236	24
178.	561	Clobetasol Propionate Cream 0.05%	20 gm Tube	230025	24
179.	562	Coal tar 4.25% and Salicylic Acid 2% Solution	50 ml	29760	24
180.	563	Dithranol Ointment IP 0.5%	20 gm Tube	6620	24
181.	564	Glycerin IP	100 gm Bottle	53504	36
182.	567	Permethrin Lotion 1%	30 ml	77545	24
183.	568	Permethrin Lotion 5%	30 ml	146330	24
184.	569	Permethrin Cream 5%	30 gm Tube in	46861	24
			unit carton		
185.	571	Povidone Iodine Ointment USP 5%	250 gm Pack	467518	24
186.	572	Povidone Iodine Solution IP 10%	100 ml Bottle	198721	24
187.	574	Spironolactone Tablets IP 50 mg	10x10 Tablet	859275	24
188.	575	Finasteride Tablets IP 5 mg	10x10 Tablet	83310	24
			strip/ blister		
189.	577	Terazosin Tablets USP 1 mg	10x10 Tablet	8055	24
190.	578	Terazosin Tablets USP 2 mg	10x10 Tablet	4147	24
191.	579	Flavoxate Tablets 200 mg	10x10 Tablet	445432	24
192.	580	Chlorhexidine Mouthwash IP 0.2%	50 ml bottle	559065	24
193.	581	Dental Gel: Choline salicylate 8.7%, Benzalkonium Chloride 0.01%, Lignocaine HCl 2% (flavoured gel	10 gm Tube	400430	24
		base)			
194.	582	Tooth Gel: Sodium Monofluorophosphate 0.7% and Potassium Nitrate 5% (in flavoured base)	50 gm Tube	493791	24

		-			
195.	583	Gum Paint containg Tannic acid 2%, Cetrimide 0.1%, Zinc Chloride 1%	15 ml squeeze vial	340795	24
196.	584	Metronidazole 1% and Chlorhexidine	10 gm Tube in	261135	24
		gluconate 0.25% Gel	unit carton	.=	
197.	585	Ciprofloxacin 0.3% and	5 ml vial with	1789186	24
		Dexamethasone 0.1% Ear Drops	sterilized		
		Ciprofloxacin and Dexamethasone	dropper, or		
		Otic Suspension USP	squeeze vial		
198.	587	Clotrimazole 1% with lignocaine 1%	5 ml ear drops	543709	24
		Ear Drops			
199.	588	Neomycin, Polymixin B and	5 ml ear drops	266070	24
		Hydrocortisone Ear Drops (Neomycin			
		sulphate 3400 IU, Polymixin B			
		Sulphate 10000 IU, and			
		Hydrocortisone 10 mg per ml)			
		Neomycin and Polymixin B Sulfate			
		and Hydrocortisone Otic Solution			
200	500	USP Comminglytic Drope (Way disselving	10 ml Bottle /	135680	24
200.	589	Ceruminolytic Drops (Wax dissolving		133080	24
		ear drops): Paradichlorobenzene 2%,	Vial (with a		
		Benzocaine 2.7%, Chlorbutol 5%,	separate		
		Turpentine oil 15%	dropper, which		
			should be able		
			to screw & cap		
			the bottle) in a		
			unit carton		
201.	590	Domeperidone Oral Drops 10 mg/ ml	10 ml Bottle	1011218	24
			(with a separate		
			dropper, which		
			should be able to		
			screw & cap the		
			bottle) in a unit		
			carton		
202.	592	Lactic Acid Bacillus Tablets 60	10x10 Tablet	11799434	24
		million spores			
203.	593	Lactulose solution USP/ BP 10 gm/ 15	100 ml Bottle	843565	24
		ml or 3.35gm/5 ml	with measuring		
			Cap		
204.	594	Liquid Paraffin IP	100 ml Bottle	185856	24
205.	596	Pantoprazole 40 mg and Domperidone	10x10 Capsule	18662870	24
		30 mg SR Capsules Pantopazole as	Strip		
		enteric coated pellets, and			
		Domperidone as sustained release			
		pellets			
206.	597	Ursodeoxycholic Acid Tablets 300	10x10 Tablet	81785	24
		mg	Strip/ blister		
207.	598	Allopurinol Tablets IP 100 mg	10x10 Tablet	140950	24
208.	599	Hydroxychloroquine Sulphate Tablets	10x10 Tablet	97570	24
	- / /	200 mg		2.2.0	_ ·
209.	600	Leflunomide Tablets 10 mg (Film	10x10 Tablet	145000	24
207.	500	coated)	TOATO TUOICE	175000	4 7
210.	601	Leflunomide Tablets 20 mg (Film	10x10 Tablet	222000	24
210.	001		TOATO TAUICI	222000	∠ '1
		coated)			65

		-			
211.	602	Sulfasalazine Delayed Release Tablets USP/ Gastroresistant Sulfasalazine Tablets BP 500 mg	10x10 Tablet	129000	24
212.	603	Gliclazide and Metformin Tablets Gliclazide 80 mg and Metformin Hydrochloride 500 mg	10x10 Tablet	858790	24
213.	604	Glucagon for Injection USP 1 mg/ml	1 ml Vial	250	24
214.	605	Medroxyprogesterone acetate Tablets IP 10 mg	10x10 Tablet	169410	24
215.	606	Testosterone Propionate Injection IP 25 mg/ 1ml	1 ml Vial	2290	30
216.	608	Octreotide Injection 50 mcg/ ml	1 ml Ampoule	5480	24
217.	609	Chlorzoxazone Tablets 250 mg	10x10 Tablet	522605	24
218.	610	Chlorzoxazone, Diclofenac Sodium & Paracetamol Tablets (Chlorzoxazone 250 mg, Diclofenac Sodium 50 mg & Paracetamol 325mg)	10x10 Tablet	8286890	24
219.	611	Betaxolol Eye Drops 0.25%	5 ml Squeeze Vial	1820	24
220.	612	Betaxolol Eye Drops 0.5%	5 ml Squeeze Vial	2820	24
221.	613	Carboxymethylcellulose Eye Drops 0.5%	10 ml Squeeze Vial	46529	24
222.	614	Phenylephrine Hydrochloride Ophthalmic Solution USP/ Phenylephrine Eye Drops BP 5%	5 ml vial with sterilized dropper, or squeeeze vial	3915	24
223.	615	Mifepristone Tablets 200 mg	Single Tablet	14000	24
224.	616	Formoterol Fumerate and Budesonide Powder for Inhalation IP 6 mcg + 200 mcg	30 Capsule (rotacaps)	861900	24
225.	617	Budesonide Powder for Inhalation 200 mcg	30 Capsule (rotacaps)	533884	24
226.	618	Ipratropium Powder for Inhalation IP 40 mcg	30 Capsule (Rotacaps)	327953	24
227.	619	Terbutaline Tablets IP 2.5 mg	10x10 Tablet	134409	24
228.	620	Xylometazoline Nasal Drops IP 0.1 %	5 ml Vial/ Bottle (with a separate dropper) in a unit carton	157885	24
229.	621	Sodium Chloride Injection IP	100 ml bottle	662560	24
230.	623	Cholecalciferol granules 60, 000 IU/gm	1 gm sachet (50 Sachets)	176100	24
231.	624	Mecobalamin Injection 500 mcg/ ml	1 ml Ampoule	248850	24
232.	626	Pyridoxine Tablets IP 10 mg	10x10 Tablet Strip	593020	36
233.	627	Pyridoxine Tablets IP 40 mg	10x10 Tablet Strip	114950	36
234.	628	Riboflavin Tablets IP 5 mg	10x10 Tablet Strip	445970	36
235.	630	Calcitriol Capsules IP 0.25 mcg	10x10 Capsule strip/ blister	1154150	24

-	ı	_	1		
236.	631	Alendronate Sodium Tablets USP /	4 Tablet	13300	24
		BP 35 mg	(20x4 Tablet)		
237.	632	Mannitol with Glycerin Injection 10%	100 ml Bottle	3754	24
		+10% w/v (For Intravenous Infusion)			
238.	635	Surfactant for intratrecheal instillation	4 ml vial	2790	18 (at 2-8°)
		(natural bovine lung surfactant)			
239.	637	Vitamin –A Capsule, Soft Gelatin	10 x 10 cap	815672	24
		Capsule contains Vit-A 50000 units	Strip		
240.	639Flu	Oseltamivir Capsule 75 mg [Each	Strip/Blister of	300000	24
		Capsule contains Oseltamivir	10 Capsules		
		Phosphate equivalent to Oseltamivir			
		75 mg]			
241.	640Flu	Oseltamivir Capsule 45 mg [Each	Strip/Blister of	100000	24
		Capsule contains Oseltamivir	10 Capsules		
		Phosphate equivalent to Oseltamivir			
		45 mg]			
242.	641Flu	Oseltamivir Capsule 30 mg [Each	Strip/Blister of	70000	24
		Capsule contains Oseltamivir	10 Capsules		
		Phosphate equivalent to Oseltamivir			
		30 mg]			
243.	642Flu	Oseltamivir Syrup. Oseltamivir	75 ml Bottle	15000	24
2 4 3.	0421 tu	2 1	with measuring	13000	24
		Phosphate for Oral Suspension 12	Cap		
		mg/ml. [Each ml contains 12 mg	Cap		
		Oseltamivir base after			
		reconstitution]			
244.	643Flu	Influenza Vaccine (A & B), H1N1	PFS	1000	24
		Vaccine [Influenza vaccine (A & B)			
		15+15 mcg, H1N1 Vaccine 15 mcg]			
	1	10.10.1008, 111111 / 400000 10 1108]	1		I

Note:-

The above quantity mentioned for this supply cum rate contract is indicative and may vary as per the actual requirement of hospitals.

The bidder should quote rate for the above mentioned packing unit only.

General Requirement:-

- 1. The manufacturer should ensure Stability of the formulations and its ingredients in the packing supplied.
- 2. The blister packing of tablets/Capsules should have Aluminium foil back.
- 3. Strip packing should be of Aluminium / Alu- Alu foils.
- 4. Aluminium foil strips refer to thickness not less than 40 microns.
- 5. The rigid PVC used in blister packing should be of not less than 250 microns.
- 6. Small tablets packed in blister should be packed to facilitate easy removal of a tablet without breaking/crushing.
- 7. Containers for 400 ml (or 400 gm) or more, should have an inner lid also.
- 8. Syrup and Suspension should be palatable enough.
- 9. The measuring cap / dropper supplied with oral liquid formulation should have suitable marking.
- 10. The minimum size (length x breadth) of a blister strip shall be 6.5cm X 3cm.
- 11. Generic name of a drug should be printed in clearly legible bold letters. The font size of the name of drug on any tablet strip/blister shall not be less than '9' in bold capital letters of Times New Roman or Arial font, e.g., LOSARTAN TABLETS IP even on small strips/blisters. The font size shall be correspondingly bigger on bigger strips / blisters. Besides this, other contents on the label should also be legible.
- 12. The stereo printing of batch no., Mfg date, Exp date on the reverse side of strip/blister should run atleast two times.
- 13. The secondary packing (unit carton) should contain 10x10 or 20x10 capsules for item code 639Flu, 640Flu and 641Flu.

RAJASTHAN MEDICAL SERVICES CORPORATION

GUIDELINES FOR BLACKLISTING/DEBARRING OF PRODUCT OR SUPPLIER/COMPANY

1. ON SUBMISSION OF FALSE, FORGED OR FABRICATED DOCUMENTS OR CONCEALING OF FACTS:

The Bidder who submits false, forged or fabricated documents or conceals facts with intent to win over the Bid or procure purchase order; Bid Security Deposit of such Bidder firm will be forfeited and firm will be liable for blacklisting for a period of not Less than 2 years. The firm will also be liable for Legal action depending on the facts & circumstances of the case.

2. ON ACCOUNT OF FAILURE TO ENTER INTO AGREEMENT OR WITHDRAWL AFTER AGREEMENT OR REFUSAL / FAILURE TO SUPPLY:

- 2.1 The successful Bidder fails to execute the agreement after being declared as L-1, L-2 or L-3 etc. to perform the obligations under the Bid conditions, Bid Security Deposit of such Bidder firm will be forfeited and firm will be liable for blacklisting for a period of not less than 2 years or the period specified in Bid document.
- 2.2 The successful Bidder after entering into an agreement withdraw or fail to honour commitments as per Bid conditions, Bid Security Deposit of such Bidder firm will be forfeited and firm will be liable for blacklisting for a period of not Less than 2 years.

3. ON ACCOUNT OF NON-SUPPLY:

- 3.1 The supplier shall start to supply according to Bid condition from the date of purchase order and shall complete the supplies within 45/60 days as mentioned in Purchase Order or as stated in Bid condition.
- 3.2 RMSC will be at liberty to accept or reject the supply made belatedly as per the terms and conditions of the Bid documents. In the event of

- acceptance of delayed supply the liquidated damages shall be imposed at the rate stipulated in conditions of the Bid document.
- 3.3 If the supplier fails to execute the purchase order and informs RMSC about its inability to execute the order and non-compliance of the purchase order due to act of vis-majeure, then the Managing Director, RMSC will issue appropriate order on merits of case.
- 3.4 If the supplier fails to execute atleast 50% of the quantity mentioned in single purchase order and such failure in supply continues for three purchase orders, then supplier firm will be liable for blacklisting for a period of not Less than 2 years. As a result such supplier will be ineligible to participate in any of the Bids for particular item(s) of drugs / medicines for a period of not less than 2 years or the period specified in Bid document.

4. ON ACCOUNT OF QUALITY FAILURE OF DRUGS & MEDICINES:

- 4.1. The drugs supplied by the suppliers to the District Drug Warehouses are quarantined and samples of each and every batch of drugs /medicines are drawn on random basis and forwarded to Quality Control Wing of RMSC at the headquarter. The samples are then sorted; common batches pooled, coded and are sent to the empanelled laboratories for quality control test as per the QC Policy of RMSC.
- 4.2. Samples of all sterile surgicals & sutures items falling in the categories of drugs will also be drawn as per above policy and all of them will be subjected essentially for sterility testing.
- 4.3. If such samples pass quality test in all respects, RMSC will instruct its Warehouses to issue items of drugs to various hospitals / institutions
- 4.4. If the sample fails in quality test and report is received certifying that sample is not of standard quality, the drugs of the batch will not qualified for issue and supplier shall be informed to take back stocks of such batch, which failed the quality test and other consequences would follow as per the conditions in the Bid documents.

- 4.5. If two batches of a particular item supplied under a Bid tenure by the supplier are declared as Not of Standard Quality by an empanelled lab or Govt. Lab in test for assay and such failures are further confirmed by another empanelled lab / Govt. Lab, then the particular item of the drug shall be liable for blacklisting for a period of not Less than 2 years.
- 4.6. If three batches of a particular item supplied under a Bid tenure by the supplier are declared as Not of Standard Quality during its entire shelf life by an empanelled lab or Govt. Lab in test for assay and / or in any other parameter(s) and if such failures are further confirmed by another empanelled lab or Govt. Lab during its entire shelf life, the particular item of the drug shall be liable for blacklisting for a period of not Less than 2 years.
- 4.7. In case three products of a company/supplier are blacklisted for supply made during a Bid duration the Supplier / Company shall be liable for blacklisting for a period of not Less than 2 years.
- 4.8. In case, any sample (even one batch) is declared as Spurious or Adulterated by an empanelled lab or Govt. Lab and if such failure is further confirmed by another empanelled lab / Govt. Lab during its entire shelf life, the Supplier / Company shall be liable for blacklisting for a period of not less than 3 years.
- 4.9. If any statutory sample of RMSC supply drug is drawn by Drugs Control Officer on suo-moto basis or on complaint and if it fails in quality parameters, the report is conclusive till it is challenged by supplier / company. If it is challenged then the report of Director, C.D.L., Kolkatta shall be conclusive and action as contemplated in foregoing paragraphs will be initiated in the matter of blacklisting of product or company. However if failure is of such nature wherein Drugs Controller of State grants prosecution sanction under Drugs & Cosmetics Act, 1940, then even failure of such one batch shall be considered adequate for blacklisting the product for not less than 2 years and in case of involvement of three different products the **Supplier / Company** as a whole shall be liable for blacklisting for a period of not Less than 3 years.

5. PROCEDURE IN THE EVENT OF QUALITY FAILURE WILLINVOLVE THE FOLLOWING STEPS:

- 5.1 On receipt of adverse quality test report from empanelled lab or Govt. Lab of a quarantined stock, instructions will be issued immediately through e-mail to the concerned District Drug Warehouses to not to release such stock and entries be made by QC Cell at headquarter in e-aushadhi software for batch rejection i.e. not to be released for distribution to institutions / DDC's.
- 5.2 Warehouse Incharge will take appropriate measures immediately to segregate such stock and label all cartons as "NOSQ Drugs-Not for release" and shift it from quarantine area to Non-Release / Rejected Drugs Area (which is under lock & key) till its lifting by the supplier.
- 5.3 Immediately on receipt of NOSQ report, the second sample should be sent to another empanelled lab / Govt. Lab by the QC Cell.
- 5.4 The supplier shall be informed immediately about the test results and instructions be issued to lift the entire stock at supplier's expenses of such batch no. drug which is declared as "NOSQ" by the empanelled lab / Govt. Lab. However, in case of serious quality failure i.e. if drug is declared or adjudged spurious, adulterated or grossly substandard, one of drug warehouse incharge will be directed to contact the District Drugs Control officer for drawing statutory sample of such batch as per Act. The DDW Incharge has to keep adequate quantity of such drug for statutory sampling by Drugs Control officer.
- 5.5 In case of drug declared as **Not of Standard Quality** on subsequent sampling after the batch was released the procedure given in sub-para 5.2 will be followed in respect of stock available with the warehouse. In respect of stock already issued and drug warehouse in charge will take immediate steps to RETRIEVE the unused stock of such drugs from all such institutions and D.D.C.s by all possible mode and means and he/she will ensure that no such NOSQ drug is further distributed to the patients and ensure effective recall.
- 5.6 On receipt of test report from empanelled lab / Govt. Lab, show cause notice will be issued immediately to the concerned supplier calling for

explanation within 3 days from the date of receipt of notice in respect of quality failure of concerned batches of drug. The supplier will be required to submit the batch manufacturing record, batch analysis report, raw material purchase record & raw material test reports etc. Opportunity for personal hearing, if desired by supplier, may also be accorded.

- 5.7 On confirmation of the test result by the second laboratory, the case will be referred to the disciplinary committee of RMSC for further action.
- 5.8 In case when the second report is contradictory to the first report, the statutory sample will be sent to Govt. Lab, whose report will be final and if the sample has been tested by the Govt. Lab at any stage, its report will be conclusive & final unless challenged as per provisions of Drugs & Cosmetics Act, 1940.

6. EXAMINATIONS OF ISSUES BY DISCIPLINARY COMMITTEE OF RMSC

- 6.1. Each & every case of submission of false documents, failure to execute agreement, non-supply or quality failure, etc. will be referred to disciplinary committee of RMSC for examination on a case to case basis for making appropriate technical recommendation to Managing Director for further appropriate action.
- 6.2. The recommendations of disciplinary committee will be placed before the Managing Director, RMSC who shall take appropriate action which may deem fit in the light of facts & circumstances of the case by way imposing penalty or debarring or Blacklisting of the particular product or supplier/company.
- 6.3. If, the quality failure is of such nature that a particular product has been blacklisted according to the procedure stated above, the supplier will not be eligible for participating in any of the Bids for the particular item floated by RMSC for the specified period. For such purpose period of blacklisting will be counted from date of issue of order and it will deemed to be over on completion of the period and as such no fresh orders will normally be required for re-eligibility purpose. Similarly if the supplier /company is blacklisted the supplier will not be eligible for

participating in any of the Bids for any of the items during blacklisted period.

7. POWER OF REVIEW:

Subsequent to the action taken on the basis of available facts if some new facts & evidences such as reversal of test results findings by Appellate Laboratories etc. are brought to the notice of the corporation, the Managing Director of RMSC will have the right to review the earlier action. He may seek advice from the disciplinary committee in such matters.

8. RIGHT TO APPEAL:

Any supplier / company against whom the above action is taken may prefer an appeal within 30 days of date of blacklisting order to the Principal Health Secretary, Medical & Health Department, Govt. of Rajasthan who shall decide the same.

9. Savings:

The blacklisting of particular product or supplier / firm will be done without prejudice to other penalty which may be imposed as per the conditions of Bid documents and also to other actions which may be initiated under Drugs and Cosmetics Act 1940 or any other law of land. RMSC will display names of such blacklisted products and companies on its website and also circulate the same among all stakeholders viz. PSME, DM&HS, DC including respective State Drug Controllers where the supplier / company is located.

10. JURISDICTION:

In the event of any dispute arising out of the orders and implementation thereof, such dispute shall be subject to the jurisdiction of the Courts of Jaipur City only or Hon'ble Rajasthan High Court, Bench at Jaipur.

EXPLANATIONS:

(i) Increase in the cost of raw materials, power cut, Labour strike, insolvency, closure of the factory would not be considered as act of vismajeure.

- (ii) The meaning of 'Spurious drugs' or 'Adulterated Drugs' will be construed in strict sense under the provisions of Drugs & Cosmetics Act, 1940. For the purpose of blacklisting a drug will be considered 'Spurious' if empanelled lab / Govt. Lab so declare the product or it is found containing either no drug or very poor drug contents on testing or it is purported to be manufactured of whom it is not truly a product or which is likely to cause grievous hurt within the meaning of Sec. 320 0f IPC. Similarly for the purpose of blacklisting a drug will be considered 'Adulterated' if empanelled lab / Govt. Lab so declare the product or it is found containing any poisonous, deleterious, harmful or toxic substances or which is likely to cause grievous hurt.
- (iii) Purchase Orders, if any, already issued before taking any blacklisting action or replacement orders given in past will not be affected in view of action taken as per above guidelines but all strict quality checks shall be observed for each supply of products.
- (iv) The action proposed as above is not in conflict to any express conditions laid down in corresponding Bid and in case of any overlapping, the Bid condition will prevail.

ANNEXURE-X FORM NO. 1 [See rule 83 of RTPP]

Memorandum of Appeal under the Rajasthan Transparency in Public Procurement Act, 2012

Appeal No
 Particulars of appellant: (i) Name of the appellant: (ii) Official Address, if any: (iii) Residential address:
Name and address of the respondent (S):(i)(ii)(iii)
3. Number and date of the order appealed against and name and designation of the officer/ authority who passed the order (enclose copy), or a statement of a decision, action or omission of the Procuring Entity in contravention to the provisions of the Act by which the appellant is aggrieved:
4. If the Appellant proposes to be represented by a representative, the name and postal address of the representative:
5. Number of affidavits and documents enclosed with the appeal:
6. Ground of appeal:
7. Prayer:
Place Date
Appellant's Signature

UNDERTAKING FOR EMPANELMENT

I	Name	S/o		Age	Prop./Partne	er/Director/
Powe	er of attorney l	holder of firm	M/s		situated at	(Complete
addr	ess of Mfg. uni	it)	bearing	drug licen	ise on Form	25 & 28 or
form	10 bearing	Number	¿	&	re	espectively,
issue	d on dated	va	lid/Renew	ed up to		do here
by de	eclare on oath a	s follows:-				

- That I have applied for empanelment for supply of Drugs & Medicines for the items I have quoted in the bid as enlisted in Annexure –VII
- 2. That I/We have carefully read all the conditions of Bid in Ref. no. F.02(126)/RMSC/PROCURMENT/DRUG/NIB-05/2014/485 Dated 12.05.2014 for supply Cum rate contract and empanelment for supply of Drug and Medicines For Rajasthan Medical Services Corporation and accept all conditions of Bid, including amendments if any.
- 3. That I will be considered empanelled for the items which are declared technically responsive.
- 4. That I have deposited the required fees for empanelment or previous bid ref no......

Date

Name & Signature with Seal

Annexure-XII Ref. Clause No.17.2

Supplier Consolidated Invoice

Comp	lete Ad	dress:									
DL NO.: TIN N					TIN No	No.:			Invoice No.:		
						Date:					
Purchaser: Managing Director					~	Purchase Order No.:					
Address: Rajasthan Medical Services C Gandhi-Block, Swasthaya Bhawan, Tila Scheme, Jaipur Phone No. 0141- 22280				Tilak Ma	lak Marg, C-			• • • • • • • • • • • • • • • • • • • •			
RMSC TIN NO.08404750762											
			4/50/62 iption:			Drug (odo (D	MSC)			
Ivaille	or rien	II/DESCI I	.puon	•••••	••••	Drug	oue (N	WISC)		••••••	•••
S.No	Name of DDW	Odered Qty.	Invoice/ Challan no.	Date	Packing Size	Batch No.	Mfg. Date	Exp. Date	Quantity Supplied in No. (Batch wise)	Basic Rate (without Concessional CST)	Basic Amount (without Concessio nal CST)
1	2	3	4	5	6	7	8	9	10	11	12
Remar	ks:						Basic Amount				
Т					Total Ta	Rate of (%) Concessional CST against C-form & Total Tax Amount					
'						TOTAL INVOICE AMOUNT					

Authorised Signatory

Annexure-XIII
Ref. Clause No. 17.2

Analytical Report Regarding Quality

Nam	e of Supplier:-					
Addı	ress:-					
PO No:- Date:-						
Drug	g Name:-					
Deta	ils of in house test	report:-				
S. No.	Name of Lab.	Test report No.	Date	Batch No.	Qty. Supplied	Result
1.						
2.						
3.						
4.						
5.						
6.						
7.						
8.						
9.						
10.						
11.						
12.						

Authorised Signatory

Security form (Bank guarantee)

To,
Managing Director Rajasthan Medical Services Corporation Ltd WHEREAS(Name of Supplier)
Hereinafter called "the Supplier" has undertaken, in pursuance of Contract (Letter of Acceptance) No
AND WHEREAS it has been stipulated by you in the said Contract that the Supplier shall furnish you a bank Guarantee from a Scheduled Bank for the sum specified therein as security for compliance with the Supplier's performance obligations in accordance with the Contract.
AND WHEREAS we have agreed to give the supplier a Guarantee: THEREFORE WE hereby affirm that we are Guarantors and responsible to you, on behalf of the Supplier, up to a total of
This guarantee is valid until the day of 2016
Signatures and Seal of Guarantors
Date
Address:

Note:- The validity of bank guarantee should be for 24 months from the date of issuance of Bank Guarantee.